Final Program
The International Society for Heart and Lung Transplantation
Twenty-Fifth Anniversary Meeting and Scientific Sessions
Philadelphia Marriott, Philadelphia, PA
April 6-9, 2005
SCIENTIFIC PROGRAM COMMITTEE

Shaf Keshavjee, MD, FRCSC, Toronto, ON, Canada, Program Chair
Alec Patterson, MD, St. Louis, MO, President
Mark L. Barr, MD, Los Angeles, CA
Gerald J. Berry, MD, Stanford, CA
Annette Boehler, MD, Zurich, Switzerland
Susan M. Chernenko, MN, Toronto, Canada
Maryann R. Chrisant, MD, Philadelphia, PA
John Dark, MB, FRCS, Newcastle Upon Tyne, United Kingdom
Duane Davis, MD, Durham, NC
Thomas J. Dengler, MD, Heidelberg, Germany
Fabienne Dobbels, MSc, Leuven, Belgium
Howard J. Eisen, MD, Philadelphia, PA
Marc Estenne, MD, Brussels, Belgium
Marshall I. Hertz, MD, Minneapolis, MN
James K. Kirklin, MD, Birmingham, AL
Robert L. Kormos, MD, Pittsburgh, PA
Kenneth R. McCurry, MD, Pittsburgh, PA
Mandeep R. Mehra, MD, New Orleans, LA
Jonathan B. Orens, MD, Baltimore, MD
Robert C. Robbins, MD, Stanford, CA
Joseph G. Rogers, MD, Durham, NC
Bruce L. Rosengard, MD, FRCS, Cambridge, United Kingdom
Gregory I. Snell, FRACP, MBBS, Prahran, Australia
Martin Struber, MD, Hannover, Germany
Thomas K. Waddell, MD, Toronto, ON, Canada
Lori J. West, MD, DPhil, Toronto, ON, Canada

ABSTRACT REVIEWERS

Nancy M. Albert, MSN, Chesterland, OH
Selim M. Arcasoy, MD, New York, NY
Abbas Ardehali, MD, Los Angeles, CA
Robert M. Aris, MD, Chapel Hill, NC
Carla C. Baan, MD, Rotterdam, The Netherlands
Wayne D. Babcock, MD, Modesto, CA
Peter Berkin, MBBS, FRAC, Melbourne, Australia
Sangeeta M. Bhorade, MD, Chicago IL
Roberta C. Bogaev, MD, San Antonio, TX
Dominic C. Borie, MD, PhD, Stanford, CA
Robert J. Boucek, Jr., MD, St. Petersburg, FL
Robert C. Bourge, MD, Birmingham, AL
Caron L. Burch, RN, MSN, FNP, Manhattan Beach, CA
Michael Burch, MD, London, United Kingdom
Margaret Burke, MB, MRCPath, Harefield, Middlesex, United Kingdom
Clifford Chin, MD, Palo Alto, CA
Jason D. Christie, MD, Philadelphia, PA
David K.C. Cooper, MD, PhD, FRCS, Pittsburgh, PA
Paul A. Corris, MD, Newcastle Upon Tyne, United Kingdom
Maria G. Crespo-Leiro, MD, La Coruna, Spain
Hiroshi Date, MD, Okayama, Japan
G. William Dec, MD, Boston, MA
Sabine M. DeGeest, RN, PhD, NFESC, Basel, Switzerland
Marc DePerrot, MD, Le Plessis-Robinson, France
Mary Amanda Dew, PhD, Pittsburgh, PA
DEVELOPMENT COMMITTEE
Mandeep R. Mehra, MD, Co-Chair
Leslie W. Miller, MD, Co-Chair
Alec Patterson, MD
Jon Kobashigawa, MD
Mark L. Barr, MD

EDUCATION COMMITTEE
Mandeep R. Mehra, MD, Chair
Shaf Keshavjee, FRCSC, MD
Alec Patterson, MD
Mark L. Barr, MD
John Dark, MD, FRCS
TBD

FINANCE COMMITTEE
Robert C. Bourge, MD, Treasurer and Chair
Mark L. Barr, MD, President-Elect
James K. Kirklin, MD
Leslie W. Miller, MD

GRANTS AND AWARDS COMMITTEE
Mark L. Barr, MD, Co-Chair
Susan Stewart, FRCPPath, Co-Chair

HISTORY AND ARCHIVES COMMITTEE
Hector Ventura, MD, Chair
David KC Cooper, MD, PhD
Sir Terence English, FRCS
Sharon Hunt, MD
James K. Kirklin, MD
Jon Kobashigawa, MD
Mandeep Mehra, MD
Alec Patterson, MD

NOMINATING COMMITTEE
Jon Kobashigawa, MD, Chair
Alec Patterson, MD
Stephan Schueler, MD
James Young, MD
Anne Keogh, MD

REGISTRY EXECUTIVE COMMITTEE
Marshall I. Hertz, MD, Medical Director
Mark M. Boucek, MD, Associate Director for Pediatric Transplantation
Mario C. Deng, Medical Director, Mechanical Circulatory Support Device Database
Leah B. Edwards, PhD, Associate Director for Data Analysis
Berkeley M. Keck, RN, MPH, Associate Director for Database Management
David O. Taylor, MD, Associate Director for Heart Transplantation
Elbert P. Trulock, MD, Associate Director for Lung Transplantation

**SCIENTIFIC COUNCIL CHAIRS**

**Cell Transplantation/Tissue Engineering**
Doris Taylor, PhD, Chair  
Bruce Rosengard, MD, Board Liaison

**Heart Failure and Transplant Medicine**
Mariell Jessup, MD, Co-Chair  
Edoardo Gronda, MD, Co-Chair  
Mandeep Mehra, MD, Board Liaison

**Infectious Diseases**
F. Kate Gould, MBBS, Chair

**Mechanical Circulatory Support Devices**
Stephen Large, FRCS, Co-Chair  
Frank Pagani, MD, Co-Chair  
James K. Kirklin, MD Board Liaison

**Nursing and Social Sciences**
Corby D’Amico, RN, MN, Co-Chair  
Michael G. Petty, MS, RN, CCNS, Co-Chair  
Katherine Hoercher, RN, Board Liaison

**Pathology and Basic Science**
Susan Stewart, FRCPath, Co-Chair  
James George, PhD, Co-Chair  
Ron Kerman, PhD, Board Liaison

**Pediatric Transplantation**
Michael Burch, MD, Co-Chair  
MaryAnne Chrisant, MD, Co-Chair  
Francesco Parisi, MD, Co-Chair  
Stuart Sweet, MD, PhD, Co-Chair  
Lori West, MD, DPhil, Co-Chair  
Steven Webber, MB, ChB, Board Liaison

**Pulmonary Arterial Hypertension**
Christopher McGregor, MD, FRCS, Co-Chair  
Jean-Luc Vachiery, MD, Co-Chair  
Keith McNeil, MD, Board Liaison

**Pulmonary Transplantation**
Allan Glanville, MD, FRACP, Co-Chair  
Jonathan Orens, MD, Co-Chair  
Keith McNeil, MD, Board Liaison
<table>
<thead>
<tr>
<th>Year Range</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>1981-1982</td>
<td>Michael Hess, MD</td>
</tr>
<tr>
<td>1982-1984</td>
<td>Jack Copeland, MD</td>
</tr>
<tr>
<td>1984-1986</td>
<td>Terence English, FRCS</td>
</tr>
<tr>
<td>1986-1988</td>
<td>Stuart Jamieson, MD</td>
</tr>
<tr>
<td>1988-1990</td>
<td>Bruno Reichart, MD</td>
</tr>
<tr>
<td>1990-1991</td>
<td>Margaret Billingham, MD</td>
</tr>
<tr>
<td>1991-1992</td>
<td>Christian Cabrol, MD</td>
</tr>
<tr>
<td>1992-1993</td>
<td>John O'Connell, MD</td>
</tr>
<tr>
<td>1993-1994</td>
<td>Eric Rose, MD</td>
</tr>
<tr>
<td>1994-1995</td>
<td>John Wallwork, FRCS</td>
</tr>
<tr>
<td>1995-1996</td>
<td>Sharon Hunt, MD</td>
</tr>
<tr>
<td>1996-1997</td>
<td>William Baumgartner, MD</td>
</tr>
<tr>
<td>1997-1998</td>
<td>Leslie Miller, MD</td>
</tr>
<tr>
<td>1998-1999</td>
<td>Alan Menkis, MD, FRCS(C)</td>
</tr>
<tr>
<td>1999-2000</td>
<td>Robert L. Kormos, MD</td>
</tr>
<tr>
<td>2000-2001</td>
<td>Anne Keogh, MBBS, MD</td>
</tr>
<tr>
<td>2001-2002</td>
<td>James B. Young, MD</td>
</tr>
<tr>
<td>2002-2003</td>
<td>Stephan Schuler, MD</td>
</tr>
<tr>
<td>2003-2004</td>
<td>Jon Kobashigawa, MD</td>
</tr>
</tbody>
</table>
PAST PROGRAM CHAIRS

1988 Los Angeles, CA
  John C. Baldwin, MD

1990 San Diego, CA
  D. Glenn Pennington, MD

1991 Paris, France
  John B. O’Connell, MD

1992 San Diego, CA
  Eric A. Rose, MD

1993 Boca Raton, FL
  Maria Rosa Costanzo, MD

1994 Venice, Italy
  John Wallwork, MBChB, FRCS

1995 San Francisco, CA
  Leslie W. Miller, MD

1996 New York, NY
  William A. Baumgartner, MD

1997 London, England
  Stephan Schueler, MD

1997 Chicago, IL
  James B. Young, MD

1998 San Francisco, CA
  Mark L. Barr, MD

1999 Osaka, Japan
  Jon Kobashigawa, MD

2000 Vancouver, Canada
  David O. Taylor, MD

2001 Washington, DC
  Robert C. Robbins, MD

2002 Vienna, Austria
  Bruce R. Rosengard, MD

2003 San Francisco, CA
  Mandeep Mehra, MD
ISHLT AWARD RECIPIENTS

LIFETIME ACHIEVEMENT AWARD

2004  Sir Magdi Yacoub, MD
1999  Keith Reemtsma, MD
1996  Norman Shumway, MD

LIFETIME SERVICE AWARD

1997  Jacques Losman
1996  Michael Kaye

ISHLT/ROCHE TRANSPLANT CAREER DEVELOPMENT AWARD

2002  Anthony Azakie, MD
2000  Gordon D. Wu, MD

ISHLT/NOVARTIS TRANSPLANT CAREER DEVELOPMENT AWARD

2004  Allan M. Ramirez, MD

ISHLT/ROCHE TRANSPLANT RESEARCH FELLOWSHIP GRANT

2004  Kendra N. Taylor, PhD
2003  Felix Fernandez, MD
2002  Ruediger Hoebelt, MD
2001  Matteo Vatta, PhD
2001  Arnar Geirsson, MD
2000  Christopher H. Wigfield, FRCS
1999  Donald Wong, PhD
       Sivasai Krovvidi, PhD
1998  Kelly S.A. Blair, MD
       A.M. El Gamel, MD
1997  Jonathen Chen, MD
       Anne K. Raisanen-Sokolowski, MD
1996  Tuija S. Ikonen, MD

ISHLT/NOVARTIS TRANSPLANT RESEARCH FELLOWSHIP GRANT

2000  Richard S. Lee, MD
1999  George Juang, MD
       Satoshi Saito, MD
1998  Margaret L. Schwarze, MD

ISHLT/FUJISAWA TRANSPLANT RESEARCH FELLOWSHIP GRANT

2004  Christian A. Gleissner, MD
2003  Ewout J. van den Bos, MD
2004  Alyssa M. Krasinskas, MD

ISHLT/ACTELION TRANSPLANT RESEARCH DEVELOPMENT AWARD

2004  Tsuyoshi Shoji, MD, PhD

ISHLT/XDX TRANSPLANT RESEARCH DEVELOPMENT AWARD
2004  Monica Zwierzchonieuska, MD

**ISHLT/WYETH-AYERST TRANSPLANT RESEARCH FELLOWSHIP GRANT**

1998  Christine L. Lau, MD

**ISHLT/ORTHO BIOTECH TRANSPLANT RESEARCH FELLOWSHIP GRANT**

1997  Owen T. Lawrence, MD
1996  Andrew F. Pierre, MD
1995  Frances L. Johnson, MD

**ISHLT TRANSPLANT RESEARCH FELLOWSHIP GRANT**

1998  Scott D. Ross, MD

**ISHLT NURSING RESEARCH GRANT**

2004  Deidre E. Logan, PhD
2003  Diane H. Leloudis, RN, MSN
2003  Janet E. Madill, PhD
2002  Annette J. De Vito Dabbs, RN, MN, PhD
2001  Lynn Doering, RN, DNSc
2000  Nancy M. Albert, MSN, RN
1999  Jeanne Salyer, PhD
1998  Katherine St. Clair, RN, MSN
1997  Eileen Collins, RN, PhD

**CAVES AWARD**

2004  M.D. Peterson, MD
2003  Sigrid Sandner, MD
2002  Peter Blaha, MD
2001  Alexander S. Krupnick, MD
2000  Michael P. Fischbein, MD
1999  Joerg Koglin, MD
1998  Carla C. Baan, MD
1997  Simon D. Eiref, MD
1996  Moninder S. Bhabra, MD
1995  Elizabeth A. Davis, MD
1994  Jobst Winter, MD
1994  Alain Chapelier, MD
1993  David Marshman, MD
1992  David P. Kapelanski, MD
1991  A. Jiminez, MD
1990  Andres J. Duncan, MD
1989  A.M. Wood, MD
1988  Charles D. Fraser, Jr., MD
1987  Wim Van Der Bij, MD
1986  Stuart J. Knechtle, MD
1985  Michael A. Breda, MD
1984  Hermann Reichenspurner, MD
1983  Robbin G. Cohen, MD
CONTINUING MEDICAL EDUCATION INFORMATION

Accreditation

This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education. The International Society for Heart and Lung Transplantation is accredited by the ACCME to provide continuing medical education for physicians. ISHLT designates this activity for a maximum of 31.25 hours in Category 1 credit toward the AMA Physician’s Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

This program has been approved for 33 Category 1 Continuing Education Points for Transplant Coordinators (CEPTs) by the American Board of Transplant Coordinators (ABTC).

This program has been approved for ___ contact hours; CERP Category A by the American Association of Critical Care Nurses (AACN).

Educational Objectives

The International Society for Heart and Lung Transplantation is a leading organization providing education for medical professionals involved in heart and lung transplantation. Because of the rapid advances in medicine in general and transplantation medicine specifically, transplant professionals are in need of regular opportunities to update and maintain their knowledge of advances and changes in transplant medicine. This meeting is designed to address their need.

Goals

To enable participants to learn about current practices, emerging technologies, and medical advances related to heart and lung transplantation and end-stage heart and lung disease; and to provide a forum for participants to engage in discussion, debate, and examination regarding the efficacy and applicability of these current practices, emerging technologies, and medical advances.

Target Audience

The audience for this program includes physicians, surgeons, scientists, nurses, and transplant coordinators engaged in the practice of heart and lung transplantation, the management and treatment of heart and lung transplant recipients, the management and treatment of patients with end-stage heart or lung disease, basic science or clinical research related to these fields, or specialties which cause them to become involved in the treatment of transplant recipients or patients with end-stage heart or lung disease.

Learning Objectives

At the conclusion of this meeting, participants should be able to:
* understand emerging developments in transplantation, including the latest in the role of tolerance and the innate immune system
* understand the potential of molecular diagnostic tools in the detection of transplant related injury and the diagnosis of rejection
* understand, identify, prevent, and treat post-transplant complications of immunosuppression including infections, renal dysfunction, and post-transplant malignancy
* compare and evaluate the relative advantages and disadvantages of various pharmacologic, non-pharmacologic, and biologic immunosuppression techniques
* understand current and developing organ preservation/reperfusion techniques and the impact of these on the transplanted organ, and use that knowledge to optimize donor selection and extend the donor pool
* compare and evaluate the advantages and disadvantages of various mechanical circulatory support systems and their associated patient selection criteria
* describe the state of the art in clinical heart and lung failure treatment and the criteria for the selection of
patients for transplant therapy
* understand current animal models of basic science immunology and their application to the transplant setting
* evaluate issues of controversy, such as age, prior transplantation, and systemic diseases, in the selection of candidates for heart and lung transplantation
* understand the pathology of acute and chronic rejection and its application in the formulation of a definitive diagnosis of rejection
* identify the issues unique to pediatric transplantation, and apply to pediatric transplantation the relevant practices and therapies of adult transplantation
* evaluate the current and developing alternatives to orthotopic transplantation, including mechanical circulatory support, xenotransplantation, cell and tissue transplantation, and a variety of surgical alternatives; assess the future of these therapies; and compare the value of these therapies as alternatives and/or bridges to transplantation
* evaluate and implement the use of alternative methods of monitoring and treating rejection
* identify, prevent, and treat donor-transmitted diseases
Disclosure

Current guidelines state that participants in CME activities should be made aware of any affiliation or financial interest that may affect a speaker's presentation. Each speaker has been requested to complete a disclosure statement. The names of the speakers declaring such affiliations are shown below. Additionally, all speakers have been asked to verbally disclose at the start of their presentation any financial interest or affiliations and to indicate if a product they are discussing is not labeled for the use under discussion or is still investigational.

<table>
<thead>
<tr>
<th>FACULTY/PRESENTATION</th>
<th>COMPANY AFFILIATION</th>
<th>RELATIONSHIP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vincent Armenti</td>
<td>Novatis, Fujisawa, Roche, Wyeth</td>
<td>Grant Research</td>
</tr>
<tr>
<td>Robin Avery</td>
<td>Roche, Medimmune, Scymy Plough</td>
<td>Consultant</td>
</tr>
<tr>
<td>Daniel Bernstein</td>
<td>XDr</td>
<td>Consultant</td>
</tr>
<tr>
<td>John Boehner</td>
<td>Arrow International</td>
<td>Consultant</td>
</tr>
<tr>
<td>Sangeeta M. Bhorade</td>
<td>Fujisawa</td>
<td>Research Grant Support</td>
</tr>
<tr>
<td>Steven Bolling</td>
<td>Oros</td>
<td>Financial Interest</td>
</tr>
<tr>
<td>Charles B. Canter</td>
<td>Novartis</td>
<td>Research Support</td>
</tr>
<tr>
<td>John V. Conte</td>
<td>Chase Medical Co.</td>
<td>Consultant</td>
</tr>
<tr>
<td>Jack Copeland</td>
<td>SynCardia Inc.</td>
<td>Financial Interest</td>
</tr>
<tr>
<td>Jacqueline Cornelissen</td>
<td>Novartis</td>
<td>Unrestricted Educational Grant</td>
</tr>
<tr>
<td>Paul Corris</td>
<td>Novartis, Roche, Chiron</td>
<td>Research Support</td>
</tr>
<tr>
<td>Lisa A. Coscia</td>
<td>Novartis, Fujisawa, Roche, Wyeth</td>
<td>Research Support</td>
</tr>
<tr>
<td>Sekhar Dharmarajan</td>
<td>Dompe</td>
<td>Consultant</td>
</tr>
<tr>
<td>David B. Dyke</td>
<td>Thoratec</td>
<td>Training Course Lecturer</td>
</tr>
<tr>
<td>Howard J. Eisen</td>
<td>Novartis, XDr</td>
<td>Consultant, Grant Support</td>
</tr>
<tr>
<td>Alex Farivar</td>
<td>Roche</td>
<td>Subsidized Research</td>
</tr>
<tr>
<td>Ronald Freundenberger</td>
<td>Medtronic</td>
<td>Research/Speaker/Consultant</td>
</tr>
<tr>
<td>Allan Glanville</td>
<td>Roche, Novartis, Mayre, Fujisawa</td>
<td>Advisory Board/Grant Support</td>
</tr>
<tr>
<td>Roland Hetzer</td>
<td>Berlin Heart</td>
<td>Consultant</td>
</tr>
<tr>
<td>Renee Howser</td>
<td>World Heart</td>
<td>Employee</td>
</tr>
<tr>
<td>Mariell Jessup</td>
<td>Acorn</td>
<td>Advisory Board</td>
</tr>
<tr>
<td>Shaf Keshavjee</td>
<td>XDr</td>
<td>Investigator, Scientific Advisory Committee</td>
</tr>
<tr>
<td>Jon Kobashigawa</td>
<td>Fujisawa, Roche, Novartis</td>
<td>Research Grants</td>
</tr>
<tr>
<td>Richard Kowalski</td>
<td>Cylex</td>
<td>Employee</td>
</tr>
<tr>
<td>Luke Lamers</td>
<td>Bristol Myers, Squibb Med Imag.</td>
<td>Grant Support</td>
</tr>
<tr>
<td>Katherine Lietz</td>
<td>La Roche Laboratories</td>
<td>Research Grants</td>
</tr>
<tr>
<td>Charles C. Marboe</td>
<td>XDr</td>
<td>Consultant</td>
</tr>
<tr>
<td>Mandeep Mehra</td>
<td>XDr</td>
<td>Consultant</td>
</tr>
<tr>
<td>Bruno Meiser</td>
<td>Roche</td>
<td>Consultant</td>
</tr>
<tr>
<td>Santiago Miriuka</td>
<td>Wyeth Canada</td>
<td>Research Grant</td>
</tr>
<tr>
<td>Robert Montgomery</td>
<td>Medimmune, Fujisawa</td>
<td>Speaker, Research Funding</td>
</tr>
<tr>
<td>Randall E. Morris</td>
<td>Novartis</td>
<td>Employee</td>
</tr>
<tr>
<td>W. Robert Morrow</td>
<td>Roche</td>
<td>Grant Support</td>
</tr>
<tr>
<td>Johannes Mueller</td>
<td>Berlin Heart</td>
<td>Board of Directors</td>
</tr>
<tr>
<td>John C. Mullen</td>
<td>Hoffman LA Roche Ltd</td>
<td>Research Support: Grant in Aid</td>
</tr>
<tr>
<td>Tofy Mussivand</td>
<td>World Heart</td>
<td>Founder and Consultant</td>
</tr>
<tr>
<td>Walter E. Pae, Jr.</td>
<td>Arrow International</td>
<td>Research Support</td>
</tr>
<tr>
<td>Heather Ross</td>
<td>Novartis, Fujisawa, Wyeth</td>
<td>Consultant, Research Funding</td>
</tr>
<tr>
<td>Mitchell Saltzberg</td>
<td>CHF Solutions</td>
<td>Consultant</td>
</tr>
<tr>
<td>Leslie M. Shaw</td>
<td>Roche, Novartis</td>
<td>Grant Support, Scientific Advisory Board</td>
</tr>
<tr>
<td>Randall Starling</td>
<td>XDr</td>
<td>Research Support</td>
</tr>
<tr>
<td>Hans U. Stempfle</td>
<td>Brallo-Byk Guiden GMBH</td>
<td>Research Grant</td>
</tr>
<tr>
<td>Gabor Szabo</td>
<td>Inotek Pharmaceuticals</td>
<td>Consultant</td>
</tr>
</tbody>
</table>
Hiroyuki Tsukui
Hannah Valantine
Jaime Villanueva
Clyde W. Yancy
James B. Young
Andreas Zuckerman

Thoratec
Novartis
Fujisawa
Scios
World Heart
Roche, Genzyme

Thomas Burnett VAD Fellow
Consultant, Clinical Research
Grant
Research/Consultant/Speaker
Consultant, Research Support
Lecturer, Grant Support
The International Society for Heart and Lung Transplantation is most grateful for the educational grants and the support of toward this Twenty Fifth Anniversary Meeting and Scientific Sessions

GOLD PARTNER
Roche
Fujisawa
Novartis

SILVER PARTNER
Chiron
XDx
THIS PAGE IS FOR Marriott MAP(S)
HOLD 4 PAGES FOR MEETING TEMPLATE
All meetings and activities will take place at the Philadelphia Marriott unless otherwise specified. All papers will be presented in English.

**WEDNESDAY, APRIL 6, 2005**

7:00 AM-1:00 PM  
ISHLT Board of Directors Meeting (Room 403)

8:00 AM-6:00 PM  
Speaker Ready Room Open (Room 502)

8:00 AM-6:00 PM  
Press Office Open (Room 404)

10:00 AM-6:00 PM  
Registration Desk Open (Ballroom Foyer)

NOON-8:00 PM  
Exhibitor Set Up (Franklin Hall)

NOON-8:00 PM  
Poster Display Session 1 Set Up (Franklin Hall)

12:30 PM-2:00 PM  
**SATELLITE SYMPOSIUM 1**  
Cutting Edge Concepts in Heart Transplantation (Salons G-L)  
Supported by an Educational Grant From Roche  
Chairs: Randall C. Starling, MD and Thomas J. Dengler, MD

12:30 PM Cardiac Allograft Vasculopathy: Where Are We in 2005? Leslie W. Miller, MD, University of Minnesota, Minneapolis, MN
12:50 PM When and Why Should we Use CNI and Steroid Sparing Strategies in Heart Transplantation? Bruno Meiser, MD, University of Munich/Grosshadern, Munich, Germany
1:10 PM Is There a Role for IL2R Induction or T-Cell Depletion in Heart Transplantation? Andreas O. Zuckermann, MD, University of Vienna, Vienna, Austria
1:30 PM What is the Current Role of Therapeutic Drug Monitoring in Heart Transplantation? Leslie M. Shaw, PhD, University of Pennsylvania, Philadelphia, PA
1:45 PM Panel Discussion

12:30 PM-3:00 PM  
**SATELLITE SYMPOSIUM 2**  
Molecular Diagnostics in Heart and Lung Transplantation (Salons ABF)  
Supported by an Educational Grant From XDx, Inc.  
Chairs: Mandeep R. Mehra, MD and Thomas K. Waddell, MD

12:30 PM Fulfilling Unmet Needs in Thoracic Transplantation, Mandeep R. Mehra, MD, Oschner Medical Institutions, New Orleans, LA
12:50 PM Update on the CARGO Trial, Howard J. Eisen, MD, Hahnemann Hospital, Philadelphia, PA
1:10 PM Practical Applications of Molecular Testing in Cardiac Transplantation, Hannah Valantine, MD, Stanford University Medical Center, Stanford, CA
1:30 PM Gene Expression Analysis in the Prediction of Primary Graft Dysfunction and LARGO Trial Update, Shaf Keshavjee, FRCSC, MD, Toronto General Hospital, Toronto, Canada
1:50 PM Gene Expression Monitoring of Acute and Chronic Lung Rejection, Marshall I. Hertz, MD, University of Minnesota, Minneapolis, MN
2:10 PM New Protein Biomarkers of Lung Rejection, Christine Wendt, MD, University of Minnesota, Minneapolis, MN
2:30 PM Panel Discussion

12:30 PM-3:00 PM
SATELLITE SYMPOSIUM 3
Transplant Immunobiology (Salon E)
Sponsored by an Educational Grant From Fujisawa
Chairs: Ronald H. Kerman, PhD, and Adriana Zeevi, PhD

12:30 PM Antibody and Cell-Mediated Immunity in Heart and Lung Transplant Recipients, Ronald H. Kerman, PhD, University of Texas Medical School, Houston, TX
12:50 PM The Virtual Crossmatch: Defining Unacceptable Donor Antigens, Nancy Reinsmoen, PhD, Duke University Medical Center, Durham, NC
1:10 PM Humorally-Mediated Lung Injury after Transplantation, Cynthia M. Magro, MD, Ohio State University, Columbus, Ohio
1:30 PM Significance of Non-HLA Antibodies in Heart and Lung Transplantation, Marlene Rose, PhD, Harefield Hospital, Harefield, United Kingdom
1:50 PM Transplantation of the Highly Sensitized Recipient, Robert A. Montgomery, MD, DPhil, The Johns Hopkins University, Baltimore, MD
2:10 PM Immunosuppressive Management of the Highly Sensitized Patient, Leslie W. Miller, MD, University of Minnesota, Minneapolis, MN
2:30 PM Panel Discussion

12:30 PM-3:00 PM
SATELLITE SYMPOSIUM 4
Managing the Transition from Child to Adult (Salon CD)
Chairs: Mark Boucek, MD and Linda Addonizio, MD

12:30 PM Managing the Transition from Pediatrics to Adult Medicine for Grown-Up Patients, Gary Webb, MD, University of Pennsylvania, Philadelphia, PA
1:00 PM Psychosocial Challenges of Transitioning Patients, Fabienne Dobbels, MSc, Katholieke University, Leuven, Belgium
1:30 PM Pregnancy Post-Transplant, Vincent T. Armenti, MD, Temple University School of Medicine, Philadelphia, PA
2:00 PM Re-Transplantation for Grown-Up Pediatric Thoracic Organ Recipients: The Pediatric and Adult Perspectives, Linda J. Addonizio, MD, Columbia Presbyterian Medical Center, New York, NY and Asif Hasan, MD, Freeman Hospital, Newcastle, United Kingdom
2:30 PM Panel Discussion

2:00 PM-2:15 PM
Coffee Break (Ballroom Pre-Function)

2:15 PM-6:00 PM
SATELLITE SYMPOSIUM 5A
Cardiopulmonary Assist Devices: Looking Beyond the Horizon (Salon G-L)
Chairs: Daniel Loisance and Stephen Large, FRCS

2:15 PM Minimally Invasive Cardiac Assist Technology, Steven F. Bolling, MD, University of Michigan Hospital, Ann Arbor, MI
2:35 PM Downsizing Cardiac Assist Devices: Pediatric Applications, Roland Hetzer, German Heart Institute, Berlin, Germany
2:55 PM The Artificial Lung: Assist to Replacement, Bartley P. Griffith, MD, University of Maryland, Baltimore, MD
3:15 PM Revolutionary Designs in Blood Pumps  
3:15 PM Ventracor, Donald S. Esmore, MBBS, FRACS, Alfred Hospital, Melbourne, Australia  
3:25 PM Heartmate III, Robert L. Kormos, MD, University of Pittsburgh Medical Center, Pittsburgh, PA  
3:35 PM DeBakey VAD, George M. Weiselthaler, MD, University of Vienna, Vienna, Austria  
3:45 PM Jarvik Heart, O. Howard Frazier, MD, Texas Heart Institute, Houston, TX  
3:55 PM Discussion

4:15 PM Break

SATellite Symposium 5B  
The Final Technology Solutions for End Stage Congestive Heart Failure (Salon G-L)  
Chairs: Jack G. Copeland, MD and Leslie W. Miller, MD

4:30 PM The Total Artificial Heart: Do We Have a Product? O. Howard Frazier, MD, Texas Heart Institute, Houston, TX  
4:50 PM Destination LVAD Therapy: Contemporary Challenges and Results, James W. Long, MD, PhD, LDS Hospital/Salt Lake Cardiovascular & Thoracic Surgery Associates, Salt Lake City, UT  
5:10 PM Alternative List Heart Transplantation Versus Destination LVADs: Is It Time for a Randomized Trial? James K. Kirklin, MD, University of Alabama at Birmingham, Birmingham, AL  
5:30 PM Will All of Our Problems be Solved by Cells? Dick Wiesel, MD,

5:50 PM Discussion

3:00 PM-3:30 PM Coffee Break (Ballroom Pre-Function)

3:30 PM-6:00 PM SATELLITE SYMPOSIUM 6  
Interactions Between Innate and Acquired Immunity in Transplantation (Salons ABF)  
Chairs: Mingyao Liu, MD and Fadi Lakkis, MD

3:30 PM Danger Signals, Polly Matzinger, PhD, National Institutes of Health, Bethesda, MD  
4:00 PM TLR Signalling in Minor and Major MHC Mismatch, Daniel R. Goldstein, MD, Yale University School of Medicine, New Haven, CT  
4:30 PM TLR4 Polymorphisms in Lung Transplantation, Scott M. Palmer, MD, Duke University, Durham, NC  
5:00 PM Adaptive Immune Responses Enhance Innate Immunity in Cardiac Transplantation, David Perkins, MD, PhD, Brigham and Women's Hospital, Boston, MA  
5:30 PM Panel Discussion

3:30 PM-6:00 PM SATELLITE SYMPOSIUM 7  
OB/BOS State of the Art (Salon E)  
Chairs: Marc Estenne, MD and Paul Corris, MD

Pathogenesis

3:30 PM Airway Remodeling: Lessons Learned from Asthma and COPD, James C. Hogg, FRCPC, St. Paul's Hospital, Vancouver, Canada  
3:45 PM Alloimmune Mechanisms: Innate Immunity, Humoral Immunity, De Novo Anti HLA Antibodies, David S. Wilkes, MD, Indiana University School of Medicine, Indianapolis, IN  
4:00 PM Non-alloimmune Mechanisms: Infectious, Glen Westall, MBBS, FRACP, Alfred Hospital, Prahan, Australia  
4:15 PM Non-alloimmune Mechanisms: Non-infectious, Annette Boehler, MD, University Hospital Zurich, Zurich, Switzerland
Treatment/Prevention
4:30 PM Fundoplication, R. Duane Davis, MD, Duke University Medical School, Durham, NC
4:45 PM Azithromycin, Jonathan B. Orens, MD, Johns Hopkins Hospital, Baltimore, MD
5:00 PM MMF – the European Trial: Comparison with Other Solid Organs, Paul A. Corris, MB, FRCP, Freeman Hospital, Newcastle, United Kingdom
5:15 PM Sirolimus – Everolimus, Gregory I. Snell, FRACP, MBBS, Alfred Hospital, Prahran, Australia
5:30 PM Therapeutic Drug Monitoring, Allan R. Glanville, MD, FRACP, St. Vincent’s Hospital, Sydney, Australia
5:45 PM Discussion

3:30 PM-6:00 PM
SATELLITE SYMPOSIUM 8
Growing Older With A Transplant (Salon CD)
Chairs: Fabienne Dobbels, MSc, and Susan M. Chernenko, MN

3:30 PM The New Generation of Older Transplant Recipients: Facts and Features, Lorraine Evangelista, RN, PhD, University of California at Los Angeles, Los Angeles, CA
3:55 PM New Approaches to the Older Patient in Transplantation: Shifting From Acute Care Models Towards Chronic Disease Management, Sabina M. De Geest, RN, PhD, NFESC, University of Basel, Basel, Switzerland
4:20 PM Psychosocial Functioning in Older Transplant Recipients: The Quantity/Quality Paradox, Debi H. Dumas-Hicks, RN, PhD, NFESC, Ochsner Medical Institutions, New Orleans, LA
4:45 PM Adherence in the Older Recipient: Grey Hair for the Health Care Professional? Carol S. Stilley, PhD, University of Pittsburgh, Pittsburgh, PA
5:10 PM Ethical Dilemmas in Older Recipients – Are We Doing Them Justice? Linda Wright, Toronto General Hospital, Toronto, Canada
5:35 PM Discussion

6:00 PM-7:00 PM
ISHLT Registry Executive Committee Meeting (Room 412)

6:30 PM-7:30 PM
Pediatric Transplantation Scientific Council Meeting (Salon ABF)
Mechanical Circulatory Support Council (Salon E)

6:30 PM-8:30 PM
Overview of research questions and designs that dovetail with busy clinical practice
Strategies to minimize costs and maximize quality of data collection
Obtaining IRB approval and informed consent
Strategies for writing high quality, publishable abstracts
Strategies for preparing and submitting publishable manuscripts

8:30 PM-9:30 PM
Nursing and Social Sciences Council Meeting (Salon CD)

THURSDAY, APRIL 7, 2005

6:00 AM-6:00 PM
Speaker Ready Room (Room 502)

7:00 AM-8:00 AM
Morning Coffee/Visit Exhibits (Franklin Hall)
7:00 AM-10:00 AM
Poster Display Set-Up continued (Franklin Hall)

7:00 AM-5:30 PM
Registration Desk Open (Ballroom Foyer)

7:00 AM-6:00 PM
Press Office Open (Room 404)

7:00 AM-6:30 PM
Exhibits Open (Franklin Hall)

7:45 AM-10:00 AM
OPENING PLENARY SESSION (Salons G-L)
Modestors: Alec Patterson, MD and Shaf Keshavjee, MD

7:45 AM Welcome, Alec Patterson, MD, ISHLT President, Washington University, St. Louis, MO
7:50 AM Scientific Program Report, Shaf Keshavjee, FRCSC, MD, ISHLT Program Chair, Toronto General Hospital, Toronto, Canada
8:00 AM Registry Report, Marshall I. Hertz, MD, Registry Medical Director, University of Minnesota, Minneapolis, MN
8:30 AM Invited Lecture: Molecular Diagnostics: State of the Art and Promise of the Future, Manikkkam Suthanthiran, MD, New York Hospital/Cornell Medical Center, New York, NY
9:00 AM Invited Lecture: Bolivia 6000 Meters: Achieving New Heights After Heart Transplant, Heather Ross, MD, University of Toronto, Toronto, Canada and Sylvain Bedard, Montreal, Canada
9:15 AM Invited Lecture: Bridges Between Innate and Acquired Immunity in Transplantation, Fadi Lakkis, MD, Yale University, New Haven, CT

10:00 AM-10:30 AM
Coffee Break/Visit Exhibits/Visit Posters (Franklin Hall)

10:30 AM-NOON
CONCURRENT SESSION 1
Prognosis After Heart Transplantation: Survival is not Enough (Salon G-L)
Modestors: Richard Rodeheffer, MD and James B. Young, MD

10:30 AM (1) Left Ventricular Systolic Dysfunction Is an Independent Predictor for Cardiac Death in Heart Transplant Recipients; K. Lietz, J.M. Herre, Cardiovascular Division, Eastern Virginia Medical School, Norfolk, VA; Sentara Cardiovascular Research Institute, Norfolk, VA
10:45 AM (2) Early Drop of Creatinine Clearance is a Strong Predictor of Long-Term Renal Dysfunction, Chronic Dialysis and Mortality After Heart Transplantation; M. Cantarovich, N. Giannetti, M.D. Edwardes, G. Fontaine, R. Cecere, Transplantation, McGill University Health Center, Montreal, Quebec, Canada
11:00 AM (3) Relevance of Soluble HLA Levels for Patients Survival After Heart Transplantation; V. Rebmann, M. Zeth, A. Dolar, H.G. Jakob, H. Grosse-Wilde, Institute of Immunology, University Hospital of Essen, Essen, Germany; Department of Thoracic and Cardiovascular Surgery, University Hospital of Essen, Essen, Germany
11:15 AM (4) Relationship Between Objective and Subjective Variables of Functional Capacity After Heart Transplantation; C. Bara, C. Kugler, E. Guetzlaff, K. Schallhorn, M. Strueber, A. Haverich, U. Tegtbur, Thoracic and Cardiovascular Surgery, Hannover Medical School, Hannover, Germany; Sportsmedizin Hannover Medical School, Hannover, Germany
11:30 AM (5) A Strategy of Aggressive Steroid Weaning and Routine Alendronate Therapy on Reducing Bone Loss Post Cardiac Transplant; G. Yong, H. Hayes, G. O'Driscoll, Cardiac Transplant Unit, Royal Perth Hospital, Perth, WA, Australia

10:30 AM-NOON
CONCURRENT SESSION 2
Beyond Quality of Life: When Nursing and Psychosocial Sciences Meet Behavior Medicine (Salon ABF)
Moderators: Michael G. Petty, MS, RN, CCNS and Bronwyn J. Levvey, RN

10:30 AM (7) Effect of Exercise Training on Weight Control in Patients With Chronic Heart Failure; L.S. Evangelista, K. Dracup, L.V. Doering, M.A. Hamilton; School of Nursing, University of California Los Angeles, Los Angeles, CA; School of Nursing, University of California San Francisco, San Francisco, CA; Ahmanson Cardiomyopathy Center, University of California Los Angeles Medical Center, Los Angeles, CA
10:45 AM (8) Hoping for the Best While Preparing for the Worst: Communication About End-of-Life Planning in Heart Transplant Programs; J. Yager; A. Hernandez, J. Tulsly, S. Russell; Cardiology, Duke University Medical Center, Durham, NC; General Medicine, Duke University Medical Center and VAMC, Durham, NC; Cardiology, Johns Hopkins Hospital, Baltimore, MD
11:00 AM (9) Longitudinal Assessment of Psychological Functioning After Paediatric Heart or Heart-Lung Transplantation; J.O. Wray, R. Radley-Smith; Department of Cardiothoracic Transplantation, Royal Brompton and Harefield NHS Trust, Harefield, Middlesex, United Kingdom
11:15 AM (10) Health-Related Quality of Life in 280 Transplant Recipients; M.A. Dew, L. Myaskovsky, A.F. DiMartini, G.E. Switzer; R.L. Kormos; Psychiatry, University of Pittsburgh School of Medicine and Medical Center, Pittsburgh, PA; Medicine, University of Pittsburgh School of Medicine and Medical Center, Pittsburgh, PA; Surgery, University of Pittsburgh School of Medicine and Medical Center, Pittsburgh, PA

10:30 AM-NOON
CONCURRENT SESSION 3
Post Transplant Complications: Heart (Salon E)
Moderators: Stephen W. Hirt, MD and Niloo M. Edwards, MD

10:30 AM (13) Preventing Cardiac Allograft Vasculopathy - Long-Term Beneficial Effects of MMF; L. Kaczmarek, P. Landwehr, B. Meiser, J. Groetznar, P. Uberfuhr, B. Reichart; Cardiac Surgery, LMU Munich, Grosshadern University Hospital, Munich, Germany
10:45 AM (14) Cutaneous Malignancies After Cardiac Transplantation - Risk Factors and Effect on Late Survival; M. Alam, D. Silber, M. Mullen, R. Brown, C. Yancy, D. Feldman, R. Oren, J. Kricklin; Dermatology, Northwestern University, Chicago, IL; Hershey Medical Center, Hershey, PA; Loyola University Medical Center, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of Texas Southwestern Medical Center, Dallas, TX; Ohio State University, Columbus, OH; University of Iowa, Iowa City, IA
11:00 AM (15) Coronary Plaque Characterization With Intravascular Ultrasound Radiofrequency Data Analysis in Transplant Vasculopathy; Early Experience; M. Vanderheyden, M. Goethals, N. Kerre, M. Walravens, M. De Proft, W. Wijns, J. Bartunek, F. Wielens; Cardiovascular Center, OLV Ziekenhuis, Aalst, Belgium; Department of Cardiac Surgery, OLV Ziekenhuis, Aalst, Belgium
11:15 AM (16) Quantitative Assessment of Cardiac Allograft Vasculopathy by Real-Time Myocardial Contrast Echocardiography; C. Uebleis, X. Hoyer, P. Ueberfuhr, H.-U. Stempfle; Department of Cardiology, Med. Poliklinik - Innenstadt, University of Munich, Munich, Germany; Department of Heart Surgery, Grosshadern, Munich, Germany
11:30 AM (17) Normalization of Right Ventricular Performance Evaluated by Magnetic Resonance Imaging (MRI) on the Late Follow-Up of Heart Transplantation(HT); Relationship Between Function, Exercise Capacity and Pulmonary Vascular Resistance; F. Bacal, P.V. Pires, J.R. Parga, M.A. Rosario-Neto, U.M. Costa, F.D. Cruz, V.S. Issa, S.M.A. Ferreira, V.M. Avila, N.A.G. Stolf, G.V. Guimaraes, E.A. Bocchi, Heart Transplant Unit, Heart Institute(InCor)-University of Sao Paulo, Brazil, Sao Paulo, Brazil
11:45 AM (18) Routine Chest CT Screening in High Risk Cardiac Transplant Patients May Improve Survival; D.H. Rosenbaum, R.A. Bhojani, P. Kaiser, E. Dikmen, M. Paul, C. Yancy, W.S. Rijn, J.M. DiMaio; Cardiovascular and Thoracic Surgery, UT Southwestern Medical Center, Dallas, TX; Internal Medicine, UT Southwestern Medical Center, Dallas, TX; Thoracic Surgery, Kirikkale University, Kirikkale, Turkey
10:30 AM-NOON
CONCURRENT SESSION 4
Immunobiology in Lung Transplantation (Salon CD)
Moderators: Si M. Pham, MD and David S. Wilkes, MD

10:30 AM (19) Donor-Specific Transfusion and Anti-CD154 Induces Tracheal Allograft Tolerance Via Peripheral Deletion and Regulatory T Cells; R.M. Aris, I.P. Neuringer, K.P. McKinnon, W.J. Bricky, D.G. Sterka, P. McNellie, J.P.Y. Ting, W. Chalermskulrat, Pulmonary Medicine and Cystic Fibrosis Center, University of North Carolina, Chapel Hill, NC; Department of Microbiology/Immunology, University of North Carolina, Chapel Hill, NC

10:45 AM (20) Simultaneous LFA-1 and CD40L Antagonism Prevents Airway Remodeling in Orthotopic Airway Transplantation: Implications for the Role of Respiratory Epithelium as an Antigenic Target and a Modulator of Fibrosis; T. Murakawa, M.M. Kerklo, M.R. Zamora, F.L. Grover, Surgery and Medicine, University of Colorado Health Sciences Center, Denver, CO

11:00 AM (21) Epithelial to Mesenchymal Transition in Clinically Stable Lung Transplant Recipients; I.A. Forrest, D.M. Murphy, J.L. Lordan, G. Pritchard, D. Jones, H. Robertson, J.E. Cawston, J.H. Dark, J.A. Kirby, C. Ward, P.A. Corris, Applied Immunobiology and Transplantation Group, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; Musculoskeletal Research Group (SCMS), University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom

11:15 AM (22) Long-Term Acceptance of Porcine Pulmonary Allografts Without Chronic Rejection; T. Shoji, A. Muniappan, D.A. Guenther, H. Sahara, J.C. Wain, S.L. Houser, R. Hasse, M. Bravard, J.C. Madsen, J.S. Allan, Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA

11:30 AM (23) Association of Vascular Endothelial Growth Factor Gene Polymorphism With Acute Rejection After Lung and Heart-Lung Transplantation; S. Datta, C. Leonard, N. Yonan, I.V. Hutchinson, Cardiothoracic Unit, Manchester Royal Infirmary, Manchester, United Kingdom; Transplant Unit, Wythenshawe Hospital, Manchester, United Kingdom; Department of Immunology, School of Biological Sciences, University of Manchester, Manchester, United Kingdom

11:45 AM (24) The Role of NKR-P1A Following Lung Transplantation; J.E. Fildes, A.H. Walker, J. Thekkudan, K. Polster, N. Yonan, I.V. Hutchinson, C.T. Leonard, The Transplant Centre, South Manchester University Hospitals NHS Trust, Wythenshawe Hospital, Manchester, United Kingdom; Department of Cardiothoracic Surgery, Northern General Hospital, Sheffield, United Kingdom; Department of Cardiothoracic Surgery, University Hospital of Wales, Cardiff, United Kingdom; Department of Immunology, School of Biological Sciences, University of Manchester, Manchester, United Kingdom

NOON-1:00 PM
Transplant Registry Meeting (Room 401)

12:15 PM-1:45 PM
LUNCHEON SYMPOSIUM
Proliferation Signal Inhibitors: Transition from Clinical Trial to Clinical Care (Salon ABF)
Supported by an Educational Grant From Novartis
Moderators: Howard J. Eisen, MD and Maria Frigerio, MD

12:15 PM Molecular Biology of Proliferation Signal Inhibitors: New Insights, Randall E. Morris, MD, Novartis Pharma AG, Basel, Switzerland

12:35 PM Prevention of Cardiac Allograft Vasculopathy in Clinical Practice, Hannah A. Valantine, MD, Stanford University School of Medicine, Stanford, CA

12:55 PM Optimizing Proliferation Signal Inhibitors and CNIs: The German Experience, Hans B. Lehmkuhl, MD, Deutsches Herzzentrum Berlin, Berlin, Germany

1:15 PM The Role of Proliferation Signal Inhibitors: Future Possibilities, Heather J. Ross, MD, FRCP, MHS, Toronto General Hospital, Toronto, Canada

1:35 PM Panel Discussion

12:30 PM-1:30 PM
MINI-ORAL POSTER PRESENTATION SESSION 1 (Salon E)
Moderators: Marlene Rose, PhD and Richard N. Pierson, III, MD

12:30 PM (25) Aging Leads to Impaired Upregulation of ICOS in Response to Allostimulation; B.M. Tesar, A. Asea, D.R. Goldstein, Internal Medicine, Section of Cardiovascular Medicine, Yale University, New Haven, CT; Center for Molecular Stress Responses, Boston Medical Center, Boston, MA
1:00 PM (43) Human Metapneumovirus Infection in Lung Transplant Recipients; Clinical Presentation and Epidemiology, C. Geitner, C. Larcher, H. Fischer, D. Nachbaur, H. Huemer, Pulmonary Medicine, LKH Natters, Natters, Austria; Hygiene and Social Medicine, Medical University Innsbruck, Innsbruck, Austria; Pediatrics, Medical University Innsbruck, Innsbruck, Austria; Hematology and Oncology, Medical University Innsbruck, Innsbruck, Austria
1:05 PM (44) Pulmonary Retransplantation for Patients With the Bronchiolitis-Obliterans-Syndrome - A Single Center Experience; J. Gottlieb, B. Gohrbandt, J. Niedermeyer, T. Welte, M. Strueber, Respiratory Medicine, Hannover Thoracic Transplant Program, Hannover Medical School, Hannover, Germany; Cardiothoracic and Vascular Surgery, Hannover Thoracic Transplant Program, Hannover, Germany
1:10 PM (45) Does Photopheresis Have a Role in the Battle Against BOS? D.C. McGiffin, R.N. Brown, J.K. Kirklin, K.H. Hart, K.R. Young, G.L. Zorn, K.J. Leon, K.M. Wille, Surgery, University of Alabama at Birmingham, Birmingham, AL; Pulmonary, University of Alabama at Birmingham, Birmingham, AL
1:15 PM (46) Single Centre Experience With Bronchial Healing after Lung Transplantation: A Review of 555 Anastomoses; M. Jeyakanthan, Q. Abid, T. Pillay, S.C. Clark, J.H. Dark, S. Schueler, Cardiopulmonary Transplantation Unit, Freeman Hospital, Newcastle upon Tyne, United Kingdom
1:20 PM (47) Daily Routine Patient-Controlled Lung Function Testing Using Electronic Spirometry Is Essential for Long-Term Outcome Following Lung Transplantation; C. Kugler, S. Fischer, J. Gottlieb, B. Gohrbandt, T. Welte, A. Haverich, M. Strueber, Hannover Medical School, Hannover, Germany; Division of Respiratory Medicine, Hannover Medical School, Hannover, Germany

1:00 PM-2:00 PM MCSD Database Meeting (Room 402)

2:00 PM-3:30 PM CONCURRENT SESSION 5

The Impact of New Technology on LVAD Implementation (Salon G-L)
Moderators: Yoshiyumi Naka, MD and George Wiesenthaler, MD

2:00 PM (48) Clinical Results of the First 99 Patients With the Axial Flow Pump INCOR; P. Göttel, R. Hetzer, C. Schmid, J. Gummert, M. Schneider, G. Gerosa, R. Tandler, D. Börmbaum, A. Schirko, R. Körfer, V. Syrvidis, F. Beyersdorf, M. Hendrikx, B. Meyns, M. Anjoline, A. Wasler, L. Liu, H.K. Najm, M. Müller, Clinical Surgery, Berlin Heart, Berlin, Germany; Deutsches Herzzentrum, Berlin, Germany; Herzzentrum Leipzig, Leipzig, Germany; Klinikum Links der Weser, Bremen, Germany; University of Padova, Padova, Italy; University of Erlangen, Erlangen, Germany; University of Regensburg, Regensburg, Germany; University Hospital St. Ekaferina, Sofia, Bulgaria; Herzzentrum NRW, Bad Oeynhausen, Germany; University of Vilnius, Vilnius, Lithuania; University of Freiburg, Freiburg, Germany; Virga Jesse Ziekenhuis, Hasselt, Belgium; University Gasthuisberg, Leuven, Belgium; Hopital Erasme, Brussels, Belgium; University of Graz, Graz, Austria; East Sino Hosp, Shanghai, China; National Guard Hospital, Riyadh, Saudi Arabia; University of Münster, Münster, Germany
2:15 PM (49) Initial Human Experience With the Terumo DuraHeart - A Magnetically Levitated Centrifugal Left Ventricular Assist System; A. El Banayosy, L. Arusoglu, P. Sarnowski, L. Kizner, G. Tenderich, C. Daqmar, R. Koerfer, Department of Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, Bad Oeynhausen, Germany
2:30 PM (50) Effect of Pulsatile And Nonpulsatile Left Ventricular Assist Devices on Plasma Renin Activity; H. Welp, C. Etz, T. Tjan, H.H. Scheld, C. Schmid, Thoracic and Cardiovascular Surgery, University Hospital Muenster, Muenster, Germany
3:00 PM (52) Does Total Implantability Reduce Infection With the Use of a Left Ventricular Assist Device (LVAD): The LionHeart™ European Experience; W.E. Paeg, J.P. Boehmner, R. Körfer, A. El Banayosy, R. Hetzer, M. Vigan, A. Pavie, Cardiothoracic Surgery and Cardiology, Pennsylvania State University, Milton S. Hershey Medical Center, Hershey, PA; Cardiac Surgery, Bad Oeynhausen Heart Center, Bad Oeynhausen, Germany; Deutsches Herzzentrum Berlin, Berlin, Germany; Cardiac Surgery, Universita Pavia-Clinico San Matteo, Pavia, Italy; Cardiovascular Surgery, Institute de Cardiologie, Paris, France
3:15 PM (53) End-Stage Cardiac Failure Managed With Levitronix® Centrimag® Short-Term Ventricular Assist Device (VAD); F. De Robertis, E.J. Birks, P. Barlow, N.R. Banner, D.F. Shore, G.D. Dreyfus, J.R. Pepper, A. Khaghani, Cardiothoracic Surgery, Royal Brompton and Harefield NHS Trust, Harefield, Middlesex, United Kingdom; Transplant Medicine, Royal Brompton and Harefield NHS Trust,
2:00 PM-3:30 PM
CONCURRENT SESSION 6
Bronchiolitis Obliterans Syndrome (Salon ABF)
Moderators: Geert M. Verleden, MD, PhD and Selim M. Arcasoy, MD

2:00 PM (54) Azithromycin Reduces Airway Neutrophilia in Patients with Bronchiolitis Obliterans Syndrome; G.M. Verleden, L.J. Dupont, B.M. Vanaudenaerde, D.E. Van Raemdonck, Respiratory Medicine, University Hospital Gasthuisberg, Leuven, Belgium; Department of Thoracic Surgery, University Hospital Gasthuisberg, Leuven, Belgium; Lung Transplantation Unit, University Hospital Gasthuisberg, Leuven, Belgium

2:15 PM (55) Autoimmunity to Collagen-V May Lead to Chronic Rejection After Human Lung Transplantation; A. Bharat, E. Trulock, G.A. Patterson, A. Aloush, T. Mohanakumar, Surgery; Pulmonology/Internal Medicine; Cardiothoracic Surgery; Pathology; Washington University, St. Louis, MO

2:30 PM (56) HLA-Specific Antibodies Are Associated With Lymphocytic Bronchiolitis and Decreased Pulmonary Function After Lung Transplantation; A.L. Giménez, R. Duquesnoy, S.A. Yousem, A.T. Iacono, K.J. Spichtet, K.R. McCurry, A. Zeevi, Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA


3:00 PM (58) Assessment of Graft Function after Single-Lung Transplantation (SLT) by Single-Breath Washout in Lateral Decubitus; A. Van Myulem, C. Knoop, M. Estenne, Department of Chest Medicine, Erasme University Hospital, Brussels, Belgium

3:15 PM (59) Role of Surfactant Proteins and Phospholipids as Markers of BOS; F. D’Ovidio, P. Hauptman, M. Liu, M. Post, S. Keshavjee, University of Toronto, Toronto, Canada; University of Sapporo, Sapporo, Japan

3:30 PM (60) Everolimus in De Novo Cardiac Transplant Recipients: 48-Month (M) Follow-Up; J.M. Hare, S. Perrone, E. Eisen, K. McCurry, P. Hauptman, S. Simonsen, M. Crespo, J. Arizon, J. Kobashigawa, J. Jarcho, Cardiology, Johns Hopkins Hospital, Baltimore, MD; Cardiaco, Fundacion Favaloro, Buenos Aires, Argentina; Cardiology, Temple University, Philadelphia, PA; Cardio/Thoracic Surgery, University of Pittsburgh, Pittsburgh, PA; Cardiology, St. Louis University Medical Center, St. Louis, MO; Surgery, Rikshospitalet, Oslo, Norway; Cardiaca, Hospital Juan Canalejo, Madrid, Spain; Cardiaco, Hospital Reina Sofia, Cordoba, Spain; Heart Transplant Program, University of California, Los Angeles, CA; Cardiology, Brigham and Woman’s Hospital, Boston, MA

2:00 PM-3:30 PM
CONCURRENT SESSION 7
Novel Immunosuppressive Strategies in Cardiac Transplantation (Salon E)
Moderators: Manfred Hummel, MD and Robert C. Bourge, MD

2:00 PM (60) Everolimus in De Novo Cardiac Transplant Recipients: 48-Month (M) Follow-Up; J.M. Hare, S. Perrone, E. Eisen, K. McCurry, P. Hauptman, S. Simonsen, M. Crespo, J. Arizon, J. Kobashigawa, J. Jarcho, Cardiology, Johns Hopkins Hospital, Baltimore, MD; Cardiaco, Fundacion Favaloro, Buenos Aires, Argentina; Cardiology, Temple University, Philadelphia, PA; Cardio/Thoracic Surgery, University of Pittsburgh, Pittsburgh, PA; Cardiology, St. Louis University Medical Center, St. Louis, MO; Surgery, Rikshospitalet, Oslo, Norway; Cardiaca, Hospital Juan Canalejo, Madrid, Spain; Cardiaco, Hospital Reina Sofia, Cordoba, Spain; Heart Transplant Program, University of California, Los Angeles, CA; Cardiology, Brigham and Woman’s Hospital, Boston, MA

2:15 PM (61) 12 Month Report of a 3 Arm Multicenter Comparison of Tacrolimus (TAC), MMF or TAC/Sirolimus (SRL) and Steroids vs Cyclosporine Microemulsion (CYA), MMF and Steroids in De Novo Cardiac Transplant Recipients; JW Kpabashigawa, MD, LW Miller, MD, GM Felker, MD, SD Russel, MD, GA Ewald, MD, M Zucker, MD, L Goldberg, MD, HJ Eisen, MD, BK Rayburn, MD, LE Wagoner, MD, E Phlibin, MD, N Pereira, MD, B Czerska, MD, RL Kormos, MD, M Weston, MD, J Conte, MD, J Hosenpud, MD, K Aaronson, MD, J Hill, MD, JG Copeland, MD, L Czer, MD, A Anderson, MD, GW Dec, MD, G Torre-Amione, MD, CW Yancy, MD, JD Vega, MD, JA Jarcho, MD, D Mančini, MD, G Bhat, MD, R First, MD, W Fitzsimmons, MS, PharmD, D Tolzman, BSBN, K Salm, BSBN, J Gao, MD, University of California, Los Angeles, CA; University of Minnesota, Minneapolis, MN; Duke University, Durham, NC; Barnes Hospital, St. Louis, MO; Beth Israel, Newark, NJ; University of Pennsylvania, Philadelphia, PA; Temple University, Philadelphia, PA; University of Alabama, Birmingham, AL; University of Cincinnati, Cincinnati, OH; Albany Medical College, Albany, NY; Medical University of South Carolina, Charleston, SC; Henry Ford Hospital, Detroit, MI; University of Pittsburgh, Pittsburgh, PA; Tampa General Hospital, Tampa, FL; Johns Hopkins, Baltimore, MD; St. Luke’s, Milwaukee, WI; University of Michigan, Ann Arbor, MI; University of Florida, Gainesville, FL; University of Arizona, Tucson, AZ; Cedars Sinai, Los Angeles, CA; University of Chicago, Chicago, IL; Massachusetts General, Boston, MA; Methodist Houston, Houston, TX; Baylor University, Dallas, TX; Emory University, Atlanta, GA; Brigham and Women’s Hospital, Boston, MA; Columbia University, New York, NY; Jewish Hospital, Louisville, KY; Fujisawa
2:30 PM (62) A 12-Month, Multicenter, Randomized, Adaptive Design, Open-Label Study To Evaluate the Benefit of C2-hr Monitoring of Neoral on Safety and Efficacy Outcomes in De Novo Cardiac Transplant Recipients Receiving Basiliximab Induction: 6-Month Outcomes; H. Ross, 1 M. Cantarovich, J. Arizon, J. Orus, L. Straatman, J. Howlett, E. Lage, M. Crespo, S. Wang, H. Haddad, L. Pulpon, N. Manito, B. Diaz Molina, M.A. Gomez, the Motown study group, Canada and Spain, 1Toronto General Hospital, University of Toronto

2:45 PM (63) Improved Safety of Basiliximab (Simulect®) Over Antithymocyte Globulin (Thymoglobulin®) Induction Therapy in Heart Transplantation; M.F. Mattei, 2 P. Boissonnat, 2 M. Redonnet, 2 I. Ganglbakch, 2 A. Mouly Bandini, 2 R. Dorent, 2 C. Yau, 2 A.S. Blanc, 2 Cardiac Surgery, Hopital Brabois, Nancy; 2Cardiac Transplantation, Hopital Cardiologique, Lyon; 2Cardiac Surgery, Hopital Ch Nicolle, Rouen; 2Cardiac Surgery, Hopital Pitie-Salpetriere, Paris; 2Thoracic Surgery, Hopital La Timone, Marseille; 2Transplantation, Novartis, Rueil, France

3:00 PM (64) The Combination of Sirolimus and Tacrolimus for Primary Immunosuppression After Heart Transplantation – Is It Worth the Effort; M. Mueller, 3 P. Kantor, 3 B. Meiser, 3 J. Groetzner, 3 I. Kaczmarek, 3 B. Reichart, 3 Department of Cardiac Surgery, Ludwig-Maximilians-University, Munich, Bavaria, Germany

3:15 PM (65) Late-Onset T-Cell Activation and Cardiac Allograft Rejection Following Cessation of Daclizumab Induction Therapy; K. Lietz, 4 E. Burke, 4 M. Mercando, 4 Y. Naka, 4 D. Mancini, 4 S. Itescu, 4 Department of Surgery and Cardiovascular Division, Columbia University, New York, NY

3:30 PM (68) Sudden Cardiac Death Prior to Pediatric Heart Transplantation: Would Implantable Defibrillators Improve Outcome? E.K. Rhee, 5 C.E. Canter, 5 S. Basile, 5 D.C. Naftel, 5 Pediatric Cardiology, St. Louis Children’s Hospital, St. Louis, MO; 5Cardiac Surgery, University of Alabama at Birmingham, Birmingham, AL

2:30 PM (69) Should Status II Patients Be Removed From the Pediatric Heart Transplant Waiting List: A Mult-Institutional Study; J.K. Kirklin, 4 D.C. Naftel, 4 F.B. Pearce, 4 C. White-Williams, 4 R.L. Caldwell, 4 H. Bartlett, 4 P. Rusconi, 4 B.V. Robinson, 4 University of Alabama at Birmingham, Birmingham, AL; 4Indiana University Medical Center, Indianapolis, IN; 4University of Iowa Hospitals and Clinics, Iowa City, IA; 4University of Miami, Miami, FL; 4University of North Carolina, Chapel Hill, NC

2:45 PM (70) Have Changes in UNOS Status System Improved Allocation in Pediatric Heart Recipients? J.J. West, 1 S.M. Pollock-BarZiv, 1 A. Ang, 1 A.I. Dipchand, 1 R. Boucek, 1 E. Blume, 1 M. Burch, 1 C. Canter, 1 J. Coe, 1 J.H. Dark, 1 B. Duncan, 1 R. Gajarski, 1 K. Kanter, 1 P. Kantor, 1 M. Kichuk-Chrisant, 1 S. Mital, 1 E. Pahl, 1 Cardiology, Hospital for Sick Children/University of Toronto, Toronto, Ontario, Canada; 1USA Centre; 3UK Centre, United Kingdom; 3Canadian Centre, Canada

2:00 PM-3:30 PM
CONCURRENT SESSION 8
Listing and Outcomes in Pediatric Thoracic Transplantation (Salon CD)
Moderators: Maryanne R. Chrisant, MD and Thomas L. Spray, MD

2:00 PM (66) Sudden Cardiac Death Prior to Pediatric Heart Transplantation: Would Implantable Defibrillators Improve Outcome? E.K. Rhee, 5 C.E. Canter, 5 S. Basile, 5 D.C. Naftel, 5 Pediatric Cardiology, St. Louis Children’s Hospital, St. Louis, MO; 5Cardiac Surgery, University of Alabama at Birmingham, Birmingham, AL

2:15 PM (67) Abo-Incompatible Infant Heart Transplantation: The World Experience; L.J. West, 1 S.M. Pollock-BarZiv, 1 A. Ang, 1 A.I. Dipchand, 1 R. Boucek, 1 E. Blume, 1 M. Burch, 1 C. Canter, 1 J. Coe, 1 J.H. Dark, 1 B. Duncan, 1 R. Gajarski, 1 K. Kanter, 1 P. Kantor, 1 M. Kichuk-Chrisant, 1 S. Mital, 1 E. Pahl, 1 Cardiology, Hospital for Sick Children/University of Toronto, Toronto, Ontario, Canada; 1USA Centre; 3UK Centre, United Kingdom; 3Canadian Centre, Canada

2:30 PM (68) Should Status II Patients Be Removed From the Pediatric Heart Transplant Waiting List: A Mult-Institutional Study; J.K. Kirklin, 4 D.C. Naftel, 4 F.B. Pearce, 4 C. White-Williams, 4 R.L. Caldwell, 4 H. Bartlett, 4 P. Rusconi, 4 B.V. Robinson, 4 University of Alabama at Birmingham, Birmingham, AL; 4Indiana University Medical Center, Indianapolis, IN; 4University of Iowa Hospitals and Clinics, Iowa City, IA; 4University of Miami, Miami, FL; 4University of North Carolina, Chapel Hill, NC

2:45 PM (69) Have Changes in UNOS Status System Improved Allocation in Pediatric Heart Recipients? J.J. West, 1 S.M. Pollock-BarZiv, 1 A. Ang, 1 A.I. Dipchand, 1 R. Boucek, 1 E. Blume, 1 M. Burch, 1 C. Canter, 1 J. Coe, 1 J.H. Dark, 1 B. Duncan, 1 R. Gajarski, 1 K. Kanter, 1 P. Kantor, 1 M. Kichuk-Chrisant, 1 S. Mital, 1 E. Pahl, 1 Cardiology, Hospital for Sick Children/University of Toronto, Toronto, Ontario, Canada; 1USA Centre; 3UK Centre, United Kingdom; 3Canadian Centre, Canada

3:00 PM (69) Should Status II Patients Be Removed From the Pediatric Heart Transplant Waiting List: A Mult-Institutional Study; J.K. Kirklin, 4 D.C. Naftel, 4 F.B. Pearce, 4 C. White-Williams, 4 R.L. Caldwell, 4 H. Bartlett, 4 P. Rusconi, 4 B.V. Robinson, 4 University of Alabama at Birmingham, Birmingham, AL; 4Indiana University Medical Center, Indianapolis, IN; 4University of Iowa Hospitals and Clinics, Iowa City, IA; 4University of Miami, Miami, FL; 4University of North Carolina, Chapel Hill, NC

3:30 PM (69) Have Changes in UNOS Status System Improved Allocation in Pediatric Heart Recipients? J.J. West, 1 S.M. Pollock-BarZiv, 1 A. Ang, 1 A.I. Dipchand, 1 R. Boucek, 1 E. Blume, 1 M. Burch, 1 C. Canter, 1 J. Coe, 1 J.H. Dark, 1 B. Duncan, 1 R. Gajarski, 1 K. Kanter, 1 P. Kantor, 1 M. Kichuk-Chrisant, 1 S. Mital, 1 E. Pahl, 1 Cardiology, Hospital for Sick Children/University of Toronto, Toronto, Ontario, Canada; 1USA Centre; 3UK Centre, United Kingdom; 3Canadian Centre, Canada

3:00 PM (70) Outcome and Obstacles in Pediatric Lung and Heart-Lung Transplantation; A.R. Simon, 1 M. Strüber, 1 A. Görlter, 1 M. Ballman, 1 S. Fischer, 1 B. Gohrbant, 1 K. Kallenbach, 1 C. Hagl, 1 J. Freihorst, A. Haverich, 1 Hannover Thoracic Transplant Program, Hannover Medical School, Hannover, Germany; 1Department of Pediatric Pneumology and Neonatology, Hannover Medical School, Hannover, Germany

3:15 PM (71) Living Donor Lobar Lung Transplantation Improves Survival Following Lung Re-Transplantation in Children; B.D. Kozower, 4 S.C. Sweet, 4 M. de la Morena, 4 P. Schuler, 4 T.J. Guthrie, 4 G.A. Patterson, 4 S.K. Gandhi, 4 C.B. Huddleston, 4 Surgery and Pediatrics, Washington University School of Medicine, St. Louis Children’s Hospital, St. Louis, MO

3:30 PM-4:00 PM
Coffee Break/Visit Exhibits/Visit Posters (Franklin Hall)

4:00 PM-5:30 PM
CONCURRENT SESSION 9
Cardiac Transplant Rejection: New Looks at an Old Hat (Salon G-L)
Moderators: Carla Baan, MD and Hannah Valantine, MD

4:00 PM (72) Gene Expression Profiling of Cardiac Allograft Recipients With Mild Acute Cellular Rejection; D. Bernstein, 4 S. Mital, 4 L. Addonizio, 4 S. Hurt, 4 M.C. Deng, 4 H. Baron, 4 S. Murali, 4 D.Y. Tayama, 4 T.M. Klingler, 4 J.G. Wohlgemuth, 4 S. Webber, 4 School of Medicine, Stanford University; 4College of Physicians and Surgeons, Columbia University; 4School of Medicine, University of Pittsburgh; 4XDx, Inc.
4:15 PM (73) The Influence of Corticosteroids on the Alloimmune Molecular Signature for Cardiac Allograft Rejection, R.C. Starling, M.C. Deng, J.A. Kobashigawa, D. Walther, J. Wohlgemuth, S. Rosenberg, M.R. Mehran, Cleveland Clinic, Cleveland, OH; Columbia University, New York, NY; University of California, Los Angeles, CA; XDx Inc; Ochsner Clinic, New Orleans, LA

4:30 PM (74) Dexamethasone at the Time of Heart Transplantation Is Not Equivalent to Methylprednisolone; S.E. Fedson, A.B. Cochrane, A.Y Kim, A.N. Husain, A.S. Anderson, Department of Medicine, Section of Cardiology, University of Chicago, Chicago, IL; Department of Pharmacology, University of Chicago, Chicago, IL; Department of Pathology, University of Chicago, Chicago, IL.

5:00 PM (76) Rejection With Hemodynamic Compromise: Objective Evidence for Efficacy of Methylprednisolone; S.E. Fedson, Brigham & Women’s Hosp, Boston, MA; VA Medical Center, Salt Lake City, UT; University of Pennsylvania, Philadelphia, PA.

5:15 PM (77) Is Routine Surveillance Biopsy Obsolete? A Multi-Institutional Analysis; J. Stehlik, R. Starling, R. Brown, J. Fanq, N. Lewis, M. Høss, M. Jessup, VA Medical Center, Salt Lake City, UT; Cleveland Clinic Foundation, Cleveland, OH; University of Alabama at Birmingham, Birmingham, AL.

5:15 PM (78) Clinical Results With the Orqis® Medical Cancion® CRS™ Therapy; B. Czerska, R.M. Oren, M. Bohm, J. Sadowsky, A.B. Van Bakel, W.T. Abraham, A. Wasler, B. Cabuay, S. Khanal, K. Bartus, M.R. Zile, M.A. Konstam, Cardiology, Henry Ford Heart & Vascular Institute, Detroit, MI; Medicine, University of Iowa, Iowa City, IA; Internal Medicine, University Hospital Saarland, Homburg, Germany; Cardiology, John Paul II Hospital, Krakow, Poland; Cardiology, Medical University of South Carolina, Charleston, SC; Cardiovascular Medicine, The Ohio State University, Columbus, OH; Surgery, University of Graz, Graz, Austria; Medicine, Tufts-New England Medical Center, Boston, MA.

4:30 PM (79) Successful Implementation of Heart Failure Self Management Tools Improves Survival; J.A. Hall, K.D. Rasmusson, T.K. French, A.G. Kfoury, L.C. Hofmann, D.G. Renlund, Heart Failure Prevention and Treatment Program, LDS Hospital, Salt Lake City, UT; UTAH Cardiac Transplant Program, LDS Hospital, Salt Lake City, UT; Division of Cardiology, University of Utah Health Science Center, Salt Lake City, UT.


4:45 PM (81) Statins Shorten QTc Interval Without Affecting Plasma BNP Levels in Patients With Advanced Heart Failure; B. Vrtovec, R. Okrajsek, A. Golicnik, M. Ferjan, P.V. Juarez, B. Radovancevic, Division of Cardiology, Ljubljana University Medical Center, Ljubljana, Slovenia; Transplant Research, Texas Heart Institute, Houston, TX.

5:00 PM (82) In the Long Term Heart Transplantation Provides Additional Benefit in Transplant Candidates With Uptitrated ACE-Inhibitor- and β-Blocker-Therapy; B. Meyer, D. Moertl, M. Huelsmann, R. Pacher, R. Berger, Department of Cardiology, Medical University of Vienna, Vienna, Austria.

5:15 PM (83) Should UNOS Status 2 Patients Be Transplanted? N.R. Shah, G.A. Ewald, D.A. Horstmanshof, E.M. Geltman, S.L. Moorhead, N. Moazami, Cardiothoracic Surgery, Washington University School of Medicine, St. Louis, MO; Cardiology, Washington University School of Medicine, St. Louis, MO.

4:00 PM-5:30 PM

CONCURRENT SESSION 10

New Insights in Heart Failure Therapy (Salon ABF)

Moderators: Joseph G. Rogers, MD and Patricia A. Uber, PharmD

4:00 PM (78) Clinical Results With the Orqis® Medical Cancion® CRS™ Therapy; B. Czerska, R.M. Oren, M. Bohm, J. Sadowsky, A.B. Van Bakel, W.T. Abraham, A. Wasler, B. Cabuay, S. Khanal, K. Bartus, M.R. Zile, M.A. Konstam, Cardiology, Henry Ford Heart & Vascular Institute, Detroit, MI; Medicine, University of Iowa, Iowa City, IA; Internal Medicine, University Hospital Saarland, Homburg, Germany; Cardiology, John Paul II Hospital, Krakow, Poland; Cardiology, Medical University of South Carolina, Charleston, SC; Cardiovascular Medicine, The Ohio State University, Columbus, OH; Surgery, University of Graz, Graz, Austria; Medicine, Tufts-New England Medical Center, Boston, MA.

4:15 PM (79) Successful Implementation of Heart Failure Self Management Tools Improves Survival; J.A. Hall, K.D. Rasmusson, T.K. French, A.G. Kfoury, L.C. Hofmann, D.G. Renlund, Heart Failure Prevention and Treatment Program, LDS Hospital, Salt Lake City, UT; UTAH Cardiac Transplant Program, LDS Hospital, Salt Lake City, UT; Division of Cardiology, University of Utah Health Science Center, Salt Lake City, UT.

4:30 PM (86) Elevated Donor Sodium Levels Are a Risk Factor for Increased 1-Year Mortality After Heart Transplantation; D. Hoefler, J.M.A. Smits, E. de Vries, H. Antretter, G. Lauffer, Department of Cardiac Surgery, University Hospital Innsbruck, Innsbruck, Austria; Eurotransplant International Foundation, Leiden, Netherlands

4:45 PM (87) Potential Suitability for Transplantation of Hearts From Human Non-Heart Beating Donors; Data Review From the Gift of Life Donor Program; A.K. Singhal, J.D. Abrams, M. Mohara, R.D. Hasz, H.M. Nathan, C.A. Fisher, S. Furukawa, B.I. Goldman, Cardiovascular and Thoracic Surgery, Pathology and Laboratory Medicine, Temple University School of Medicine, Philadelphia, PA; Gift of Life Donor Program, Philadelphia, PA

5:00 PM (88) CABG-Patched Donor Hearts: The Long Term Outcome; J. Odim, H. Laks, N.P. Almeda, J.K. Patel, J.A. Kobashigawa, Cardiothoracic Surgery, University of California at Los Angeles, Los Angeles, CA

5:15 PM (89) Free Radical Scavenger MCI-186 Ameliorates Reperfusion Injury in Hearts Harvested From Non-Heart-Beating Donors; Y. Kotani, H. Antretter, University Hospital Innsbruck, Innsbruck, Austria; Eurotransplant International Foundation, Leiden, Netherlands

4:00 PM-5:30 PM CONCURRENT SESSION 12 Primary Graft Dysfunction: Lung (Salon CD)

Moderators: Hiroshi Date, MD and Dirk Van Raemdonck, MD, PhD

4:00 PM (90) ISHLT PGD Grade Predicts Differential Mortality Following Lung Transplantation; J.D. Christie, V.N. Ahya, J.S. Sager, A. Pochchietto, E. DeMissie, L. Zhou, R.M. Koltoff, Pulmonary and Critical Care Medicine, University of Pennsylvania, Philadelphia, PA; Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA; Thoracic Surgery, University of Pennsylvania, Philadelphia, PA

4:15 PM (91) Validation of the Proposed ISHLT Grading System for Primary Graft Dysfunction Following Lung Transplantation; M.E. Prekker, D.S. Nath, A.C. Johnson, A.R. Walker, M.I. Hertz, P.S. Dahlberg, Cardiovascular and Thoracic Surgery, University of Minnesota, Minneapolis, MN; Medicine, University of Minnesota, Minneapolis, MN

4:30 PM (92) Pulmonary Microcirculation After Clinical Lung Transplantation: In Vivo Intravitalmicroscopy; V. Milekhin, I. Aleksic, U. Herold, R. Raquette, H. Jakob, Thoracic- and Cardiovascular Surgery, West German Heart Center Essen, University Hospital Essen, Essen, Germany; Pneumology, Ruhrlandklinik, University Hospital Essen, Essen, Germany

4:45 PM (93) Dilatation of Alveolar Capillaries After Lung Transplantation: Effects of Denervation; V. Milekhin, M. Kamler, N. Pizanis, T. Ley, H. Jakob, Department of Thoracic- and Cardiovascular Surgery, West German Heart Center Essen, University Hospital Essen, Essen, Germany

5:00 PM (94) Effect of Donor Alcohol Consumption on Survival After Lung Transplantation; D. Hall, T.K. Waddell, A.F. Pierre, S. Keshavjee, D. Hadjiliadis, Toronto Lung Transplant Program, University of Toronto, Toronto, Ontario, Canada

5:15 PM (95) Evaluation of the Oxygenation Ratio in the Definition of Early Graft Dysfunction Post Lung Transplantation; T. Oto, B.B. Levvey, D.V. Pilcher, M.J. Bailey, G.I. Snell, Heart & Lung Transplant Unit, The Alfred Hospital, Melbourne, Victoria, Australia

5:30 PM-6:30 PM GENERAL POSTER SESSION/Wine and Cheese Reception (Franklin Hall)

(268) Early Goal Directed Therapy for Acutely Decompensated Heart Failure: Improving Clinical and Financial Outcomes for DRG127; M.T. Saltzberg, M.R. Costanzo, V. Gupta, Midwest Heart Foundation, Downers Grove, IL; Data and Clinical Information, Cardinal Health, Naperville, IL

(269) Importance of Left Atrial Volume in Predicting Reduced Peak Aerobic Capacity in Advanced Systolic Dysfunction; R.V. Milani, C.T. Davis, C.J. Lavie, M.R. Mehran, Cardiomyopathy and Heart Transplantation Center, Ochsner Clinic Foundation, New Orleans, LA

(270) Acute Short Term Ultrafiltration Produces Sustained Hemodynamic Benefits in Acutely Decompensated Heart Failure Patients; M.T. Saltzberg, A. Neumann, M.R. Costanzo, Echocardiographic Core Laboratory, Midwest Heart Foundation, Downers Grove, IL; Midwest Heart Specialists, Naperville, IL

(271) Cardiac Resynchronization Therapy in End Stage Heart Failure Patients Listed for Cardiac Transplant; M.S. Bedi, V. Gujral, R. Kormos, S. Murali, Cardiovascular Institute, University of Pittsburgh, Pittsburgh, PA

(272) Characteristics of Patients With Stage D Heart Failure: Initial Report From the Acute Decompensated Heart Failure National Registry Longitudinal Module (ADHERE®-LM); C.W. Yancy, G.J. Fonarow, The ADHERE Scientific Advisory Committee, Cardiology, UT Southwestern Medical Center, Dallas, TX; Cardiology, University of California, Los Angeles, CA; Medical Affairs, Scios Inc., Fremont, CA
(273) Change in Plasma Brain Natriuretic Peptide Is a Strong Predictor of Prognosis in Patients With Advanced Heart Failure Awaiting for Cardiac Transplantation; G. Campano, 1 M. Pasotti, 2 R. Albertini, 2 S. Quarta, 1 A. Vegni, 1 M. Bongiorni, 1 I. Tavazzi, 1 Cardiologia, Policlinico San Matteo, Pavia, Italy; Laboratory of Clinical Chemistry, Policlinico San Matteo, Pavia, Italy; Biometry and Clinical Epidemiology, Policlinico San Matteo, Pavia, Italy

(274) Body Temperature Less Than 97.0 Degrees Fahrenheit Is Associated With Increased B-Type Natriuretic Peptide and Worse Response to Therapy in Heart Failure Patients; R.M. Delgado, 1 G. Poulin, 2 B. Radovanec, 1 B. Vrtovec, 3 K. Albright, 4 B. Kar, 4 Transplant Research, Texas Heart Institute, Houston, TX; Heart Failure Department, St. Luke’s Episcopal Hospital, Houston, TX

(275) Maturity and Adherence in Adolescent Heart Recipients; C.S. Stolley, 1 K. Lawrence, 2 A. Bender, 1 E. Olsansky, 1 S. Webber, 1 M.A. Dew, 1 School of Nursing, University of Pittsburgh, Pittsburgh, PA; Pediatric Heart & Lung Transplantation, Children’s Hospital of Pittsburgh, Pittsburgh, PA; Psychiatry, University of Pittsburgh, Pittsburgh, PA; Psychology, University of Pittsburgh, Pittsburgh, PA; Epidemiology, University of Pittsburgh, Pittsburgh, PA

(276) Depressive Symptoms in Heart Transplant Recipients in an Alternate List Program; J. Yager, 1 K. Barbour, 5 R. LaCaille, 5 M. Felker, 5 A. Hernandez, 5 S. Russell, 5 C. Milano, 5 E. Stone, 6 A. Brosse, 6 J. Blumenthal, 4 Duke University Medical Center, Durham, NC; Psychology, Duke University Medical Center, Durham, NC

(277) The Nature of a Healthy Transition After Lung Transplantation; A. De Vito Dabbs, 2 K.R. McCurry, 2 Thoracic Transplant Unit, Great Ormond Street Hospital, London, United Kingdom; Department of Cardiothoracic Transplantation, Royal Brompton and Harefield NHS Trust, Harefield, Middlesex, United Kingdom

(278) College Students Perceptions About Organ Donation; K.P. Boland, 1 College of Business, University of Pittsburgh, Pittsburgh, PA; School of Medicine, University of Pittsburgh, Pittsburgh, PA

(279) Evaluation of a Psychological Intervention (Structured Activity Camp) To Reduce Anxiety and Enhance Self-Esteem in Adolescents Post-Transplant; T. Lunnun-Wood, 1, J. Wray, 1, P. Whitmore, 1, R. Radley-Smith, 1, P. Aurora, 4, M. Elliott, 2 Department of Cardiopulmonary Transplant, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom; Department of Cardiothoracic Transplantation, Royal Brompton and Harefield NHS Trust, Harefield, Middlesex, United Kingdom

(280) Impact of Chronic Renal Dysfunction on Long Term Survival and Quality of Life in Pediatric Thoracic Transplants; R. Radley-Smith, 1, N.R. Banner, 4, M. Carby, 5, J.O. Wray, 2 Department of Cardiothoracic Transplantation, Royal Brompton and Harefield NHS Trust, Harefield, Middlesex, United Kingdom

(281) Efficacy of Implantable Cardioverter Defibrillator in Children With Dilated Cardiomyopathy; P. Rusconi, 1 D. Lage, 1 E.R. Rosenkranz, 1 G.S. Wolff, 1 M.-L. Young, 1 Pediatrics, University of Miami School of Medicine, Miami, FL; Surgery, University of Miami School of Medicine, Miami, FL

(282) High Prevalence of Gastroesophageal Reflux in Children Post Lung Transplantation - A Single Center Experience; C. Benden, 1 P. Aurora, 1 J.I. Curry, 1 P. Whitmore, 1 M.J. Elliott, 2 Cardiopulmonary Transplant Unit, Great Ormond Street Hospital for Children, London, United Kingdom; Neonatal and Pediatric Surgery Directorate, Great Ormond Street Hospital for Children, London, United Kingdom

(283) Recurrence of Coronary Artery Disease in Children After Re-transplantation; M.A. Kuhn, 1 D.D. Deming, 2 R.E. Chinnock, 2 A.J. Razzouk, 2 R.L. Larsen, 3 Pediatrics, Loma Linda University Children’s Hospital and Medical Center, Loma Linda, CA; Cardiothoracic Surgery, Loma Linda University Children’s Hospital and Medical Center, Loma Linda, CA

(284) Conversion From Trough (C0) to 2 Hour (C2) Monitoring of Cyclosporine Level in Pediatric Heart Transplant Patients- An Intent-To-Treat Study; C.E. Canter, 1 S.P. Hmie1, 1 R.W. Shepherd, 2 S.A. Lassa-Collins, 2 M. Landt, 1 Pediatrics, Washington University, St. Louis, MO; Department of Virology, Great Ormond Street Hospital for Children, London, United Kingdom

(285) Pre-Transplant Parental Psychosocial Assessment Predicts Medical Outcome in Children After Orthotopic Heart Transplantation; D.M. Stone, 1 J. Dupuis, 1 J. Leslesi, 2 D. Allasio, 1 T.P. Singh, 1 Pediatrics, Children’s Hospital of Michigan, Detroit, MI

(286) Monitoring of Epstein-Barr Viral Load in Pediatric Heart and Lung Transplant Recipients by Real Time PCR; C. Benden, 1 P. Aurora, 1 M. Burch, 1 D. Cubitt, 2 M.J. Elliott, 2 Cardiopulmonary Transplant Unit, Great Ormond Street Hospital for Children, London, United Kingdom; Department of Virology, Great Ormond Street Hospital for Children, London, United Kingdom

(287) Role of Ralnetmycin in Pediatric Heart Transplant Patients; I.C. Balfour, S.W. Snun, E.G. Wood, C.W. Belsha, D.L. Marshall, B.R. Fremd, Department of Pediatrics, St. Louis University School of Medicine, St. Louis, MO

(288) Intravenous Steroids Do Not Increase Perioperative Airway Complication Risk in Pediatric Lung Transplant Patients; J. Nigro, 1 M.V. Horn, 1 V.A. Starnes, 1 M.L. Barr, 1 M.S. Woo, 1 Cardiothoracic Surgery, Childrens Hospital Los Angeles, Los Angeles, CA

(289) Autologous Tissue Engineered With Mesenchymal Stem Cells for Cardiac Repair After Myocardial Infarction in Rats: Feasibility and Histological Data; P. Maureira, 1 J. Nloga, 1 Y. Grignon, 1 Y. Li, 1 T. Lacrouts, 1 P. Groubatch, 1 J.-F. Stoltz, 1 J.-P. Villemot, 3 N. Tran, 1 Laboratory of School Surgery, Faculty of Medicine-Nancy, Nancy, France; Laboratory of Pathology, University Hospital Center of Nancy, Nancy, France; Department of Cell Therapy and Tissue Engineering, UMR-CNRS 7563, Faculty of Medicine-Nancy, Nancy, France
(306) Poly (ADP-ribose) Polymerase Inhibition Improves Cardiac Function During Cardiac Rejection; G. Szabo, S. Hagl, C. Szabo, Department of Cardiac Surgery, University of Heidelberg, Heidelberg, Germany; 2Inotech Pharmaceuticals Corporation, Beverly, MA.

(307) Glucocorticoids Prior to Brain Death Shift the Balance between Pro- and Anti-Inflammatory Mediators in the Myocardium; K.M. McLean, J.M. Lyons, J.Y Duffy, S. Akhter, C.J. Wagner, J.M. Pearl, Department of Surgery, University of Cincinnati, Cincinnati, OH; 2Department of Cardiothoracic Surgery, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH.

(308) Right Ventricular Pressure Load in Pigs: Progressive Loss of Contractility w/o Ischemia and Downregulation of Ca2+ Handling Proteins; M. Coulibaly, H. Doerge, C. Muehlfeld, F.A. Schoendube, Cardiothoracic and Vascular Surgery, University Hospital, Göttingen, Germany; 2Department of Anatomy, University Hospital, Göttingen, Germany.

(309) VEGF and PDGF Have Distinct Roles in Development of Experimental Obliterative Bronchiolitis - A Therapeutic Approach; M. Hollmen, J.M. Tikkanen, P.K. Koskinen, K.B. Lemström, Transplantation Laboratory, Helsinki University, Helsinki, Finland.

(310) Deletion of Alloreactive Cells in Neonatal Induction of Cardiac Allograft Acceptance by Splenocytes vs Fetal Liver Cells; L. Mai, K.S. Tao, H. Lang, J.W. Chamberlain, L.J. West, Cardiology and Immunology, Hospital for Sick Children/University of Toronto, Toronto, Ontario, Canada.

(311) The Role of Alloantibody in Neonatally-Induced Cardiac Allograft Acceptance; K. Parameswaran, K. Tao, L. Mai, K. Tyerman, X. Fan, L.J. West, Cardiology and Immunology, Hospital for Sick Children/University of Toronto, Toronto, Ontario, Canada.

(312) Cytokines Have a Preventive Effect on Heart Rejection by Downregulation of Innate Immunity and Mesenchymal Growth; K.F. Remund, Z. Guo, T. Rechsteiner, M. Hofer, P. Vogt, E.W. Russi, A. Boehler, Division of Pulmonary Medicine and Lung Transplant Program, University Hospital, Zurich, Switzerland; 2Department of Pathology, University Hospital, Zurich, Switzerland.

(313) Additional VLA 4 Blockade Increases Immunosuppressive Properties of Cyclosporine A After Cardiac Transplantation; M.H.C. Richter, H. Bittner, M. Barten, J. Gummert, F. Mohr, University of Leipzig, Heart Center of Leipzig, Leipzig, Germany.


(317) The Cellular Infiltrate in the Human Artery Wall with Transplant Coronary Artery Disease: A Th-Helper 1 Memory Response; J. van Kuik, J. van Loosdrecht, D.F. van Wicher, M.F.M. van Oosterhout, A.H. Bruggink, C.C. Baan, N. de Jonge, F.H.J. Gmelig-Meyling, R.A. de Weger, Pathology, University Medical Centre Utrecht, Utrecht, Netherlands; 2Internal Medicine, Erasmus Medical Center, Rotterdam, Netherlands.

(318) Abdominal Only Approach for HeartMate LVAD Pump Replacement; A.H. Healy, K.E. Nelson, R. Khodaverdian, J.W. Long, 2Utah Artificial Heart Program, LDS Hospital, Salt Lake City, UT.


(320) Increased Incidence of Bridge-to-Recovery with Resynchronization Therapy in Patients With Idiopathic Dilated Cardiomyopathy Supported by LVAS; M. Nishimura, S. Kyo, M. Ogiwara, M. Ishikawa, Cardiovascular Surgery, Saitama Medical School, Iruma County, Saitama, Japan.

(321) Stroke Complications Following Implantation of the Cardiowest Total Artificial Heart: University of Arizona Experience; P.E. Nolan, F.A. Arabia, R.G. Smith, G.K. Sethi, P.H. Tsau, D.M. McClellan, M.S. McCartney, M.J. Steipen, J.G. Copeland, Pharmacy Practice and Science, University of Arizona, Tucson, AZ; 2Cardiovascular and Thoracic Surgery, University of Arizona, Tucson, AZ; 2Marshall Foundation Artificial Heart Program, University Medical Center, Tucson, AZ; 2Transplantation Service, University Medical Center, Tucson, AZ; 2Internal Medicine, University of Arizona, Tucson, AZ.

(322) Stroke Following Left Ventricular Assist Device Implantation Increases Length of Stay but Does Not Decrease Survival; N.C. Dang, J. Kay, V.K. Topkara, M.L. Mercando, K.H. Kruger, M.C. Oz, Y. Naka, Surgery, Columbia-Presbyterian Medical Center, New York, NY.


(324) Left Ventricular Assist Device Implantation Is Associated With Improvement in Renal Function Among Patients With Preimplant Renal Insufficiency; J. Butler, R.L. Housel, C. Gelsburg, R.N. Pierson III, 3Cardiology Division, Vanderbilt University Medical Center, Nashville, TN; 3World Heart Inc., Oakland, CA; 3Division of Cardiac Surgery, University of Maryland Medical Center, Baltimore, MD.
Improved Results Treating Primary Lung Allograft Failure Using Veno-Venous Extracorporeal Membrane Oxygenation (ECMO); M.G. Hartwig, J.Z. Appel, S.S. Lin, S. Simsr, R. Messier, R. Davis, 1 Department of Surgery, Duke University, Durham, NC

Reversal of Pulmonary Hypertension With LVAD Therapy; M. Tierney, R.E. Southard, D.L. Joyce, G.P. Noon, M. Loebe, M.M. Koerner, M. Loebe, M.M. Koerner, G. Torre-Amione, Surgery, Baylor College of Medicine, Houston, TX; "Cardiology, Baylor College of Medicine, Houston, TX

Continuous Aortic Flow Augmentation Using the Orqis® Cancion® CRS™ Therapy in Patients with Severe Heart Failure: Determinants of the Hemodynamic Response; M.R. Zile, R.M. Oren, M. Bohm, J. Sadowski, A.B. Van Bakel, B. Czerska, W.T. Abraham, A. Wasler, B. Cabuay, K. Bartus, M.A. Konstam, Medicine, MUSC, Charleston, SC; "Medicine, University of Iowa, Iowa City, IA; "Internal Medicine, University Hospital Saarland, Homburg, Germany; "Cardiology, John Paul II Hospital, Krakow, Poland; "Cardiology, Henry Ford, Detroit, MI; "Medicine, Ohio State, Columbus, OH; "Transplantation, University Hospital Graz, Graz, Austria; "Medicine, Tufts-New England MC, Boston, MA

Salvage Ventricular Assistance for Patients Undergoing Cardiopulmonary Resuscitation: Long Term Results; G. Bolotin, J. Raman, N. Thomas, V. Jeevanandam, Section of Cardiac and Thoracic Surgery, The University of Chicago, Chicago, IL

Comparison of Infections in the Cardiowest TAH, the Novacor Left Ventricular Assist System and the Thoratec Ventricular Assist Device in 137 Patients; T.K. Burke, H.R. Bradshaw, R.G. Smith, F.A. Arabia, M. McCarthy, J.G. Copeland, Artificial Heart Program, University Medical Center, Tucson, AZ; "Sarver Heart Center, University of Arizona, Tucson, AZ

Brain Natriuretic Peptide Levels in Serum and Heart in Patients Supported With a Left Ventricular Assist Device; A.H. Bruggink, D.F. van Wichen, J. van Kuik, F.H.J. Gmelig-Meyling, R.A. de Weger, N. de Jonge, Pathology, University Medical Center Utrecht, Utrecht, Netherlands; "Heart Lung Center, Utrecht, Netherlands

Successful Aggressive Withdrawal of Prednisone for De Novo Heart Transplant Patients in the Era of Modern Immunosuppression; M.S. Levy, C. Imai, A.-M. Kaan, L. Straatman, A. Ignaszewski, Cardiology, St. Paul's Hospital, Vancouver, Canada

Lower Incidence of Graft Vasculopathy (CAD) and Better Survival of Patients with Developed CAD: Potential Impact of Different Regimens; E. Szent-Ivanyi, A. Aliabadi, D. Dunkler, S. Rödler, A. Kocher, M. Grimm, E. Wolner, A. Zuckermann, Department of Cardio-Thoracic Surgery, Medical University of Vienna, Vienna, Austria

Maintenance Immunosuppression with Mycophenolate Mofetil: Long-Term Efficacy After Heart Transplantation; M. Dandel, H. Lehmkuhl, C. Knoßalla, O. Grauhan, R. Hetzer, Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany

6:00 PM - 7:00 PM Heart Failure and Transplant Medicine Scientific Council Meeting (Room 412)
Pulmonary Transplantation Scientific Council Meeting (Room 401)
Infectious Disease Scientific Council Meeting (Room 402)

7:00 PM – 8:00 PM Bus departure to National Constitution Center

7:30 PM – 8:30 PM Poster Display Session 1 Tear-Down (Franklin Hall)

7:30 PM-10:00 PM PRESIDENT’S GALA RECEPTION
(National Constitution Center)

FRIDAY, APRIL 8, 2005

6:00 AM-6:00 PM Speaker Ready Room (Room 502)

7:00 AM-8:00 AM Morning Coffee/Visit Exhibits (Franklin Hall)

7:00 AM-5:30 PM Registration Desk Open (Ballroom Foyer)

7:00 AM-6:00 PM
8:00 AM **Presidential Address**, Alec Patterson, MD, ISHLT President, Washington University, St. Louis, MO

8:30 AM (96) **Featured Abstract Presentation**: Results of a Multicenter Randomized Clinical Trial for the Assessment of a Cardiac Support Device in Patients with Heart Failure; D.L. Mann, 1 M.A. Acker, 2 M. Jessup, 2 H.N. Sabbah, 3 R.C. Starling, 4 S.H. Kubo, 5 Baylor College of Medicine, Houston, TX; 2University of Pennsylvania, Philadelphia, PA; 4Henry Ford Health Care System, Detroit, MI; 5The Cleveland Clinic Foundation, Cleveland, OH; 6Acorn Cardiovascular, Inc., St. Paul, MN

8:45 AM (97) **Featured Abstract Presentation**: Successful Bridge to Clinical Lung Transplantation Using the Pumpless Extracorporeal Lung Assist Device Novalung® in Patients With Severe Ventilation-Refractory Hypercapnia; S. Fischer, 1 A. Meyer, 1 B. Gohrbandt, 1 A. Simon, 1 J. Gottlieb, 1 T. Welle, 1 A. Haverich, 1 M. Struber, 1 Hannover Thoracic Transplant Program, Hannover Medical School, Hannover, Germany

9:00 AM (98) **Featured Abstract Presentation**: Initial Multicenter Clinical Results With the Heartmate® II Axial Flow Left Ventricular Assist Device; F.D. Pagani, 1 M. Strueber, 2 Y. Naka, 3 R.L. Kormos, 4 J.W. Long, 5 R.D. Dowling, 6 H.T. Massey, 7 D.J. Farrar, 8 O.H. Frazier, 9 University of Michigan, Ann Arbor, MI; 2Medizinisch Hochschule, Hannover, Germany; 3Columbia University, New York, NY; 4University of Pittsburgh, Pittsburgh, PA; 5LDS Hospital, Salt Lake City, UT; 6University of Louisville, Louisville, KY; 7University of Rochester, Rochester, NY; 8Thoratec Corporation, Pleasanton, CA; 9Texas Heart Institute, Houston, TX

9:15 AM (99) **Featured Abstract Presentation**: Outcome of Children Bridged to Transplant With Ventricular Assist Devices: A Multi-Institutional Study; E.D. Blume, 1 D.C. Naftel, 2 H.J. Bastardi, 3 B.W. Duncan, 3 J.K. Kirklin, 2 S.A. Webber, 4 Department of Cardiology, Children’s Hospital Boston, Boston, MA; 2Department of Surgery, University of Alabama, Birmingham, AL; 3Pediatric and Congenital Heart Surgery, Cleveland Clinic Foundation, Cleveland, OH; 4Pediatric Cardiology, University of Pittsburgh Children’s Hospital, Pittsburgh, PA

9:30 AM **Invited Lecture**: Future of Mechanical Support: A Global Perspective, Timothy Baldwin, PhD, National Institutes of Health, Bethesda, MD

10:00 AM-10:30 AM

Coffee Break/View Exhibits/View Posters (Franklin Hall)

10:30 AM-NOON

**CONCURRENT SESSION 13**

**Selection of LVAD Recipients and Effect on Outcome (Salon G-L)**

Moderators: Martin Struber, MD and Roberta C. Bogaev, MD

10:30 AM (100) Favourable Results of Mechanical Circulatory Support Extended Beyond One Year; M.J. Jurmann, 1 Y. Weng, 2 T. Drews, 2 M. Pasic, 2 E. Hennig, 2 J. Mueller, 2 R. Hetzer, 1 Herz-, Thorax- und Gefässchirurgie, Deutsches Herzzentrum Berlin, Berlin, Germany

10:45 AM (101) Bridge to Eligibility: LVAS Support in Patients With Relative Contraindications to Transplantation; J.B. Young, 1 J.G. Rogers, 2 P.M. Porthor, 2 P.E. Oyer, 2 B.S. Edwards, 2 S.F. Davis, 2 T.B. Icenogle, 2 F.L. Johnson, 3 R.L. Kormos, 4 S.L. Lansman, 4 S.W. Restaino, 4 Center, Cleveland Clinic, Cleveland, OH; 2Washington University, St Louis, MO; 3Stanford University, Stanford, CA; 4Mayo Clinic, Rochester, MN; 5Vanderbilt University, Nashville, TN; 6 Sacred Heart Medical Center, Spokane, WA; 7University Maryland, Baltimore, MD; 8University Pittsburgh, Pittsburgh, PA; 9Mt Sinai, New York, NY; 10Presbyterian Hospital, New York, NY

11:00 AM (102) Post-Transplant Survival in Older Patients Bridged to Heart Transplant With Left Ventricular Assist Device Support; D.B. Dyke, 1 P. Malani, 1 F.D. Pagani, 2 S. Wright, 1 M. Daly-Myers, 2 K. Aaronson, 1 T. Koelling, 1 R. Baliga, 1 J. Matthews, 1 A. Wu, 1 Division of Cardiovascular Medicine,
University of Michigan Health System, Ann Arbor, MI; 2Section of Adult Cardiac Surgery, University of Michigan Health System, Ann Arbor, MI

11:15 AM (103) Clinical Outcomes With Mechanical Circulatory Support Devices: A Retrospective Analysis of the Impact of Age in 1,365 LVAD Recipients; T. Mussivand, 1 D.A. Hasle, 1 K.S. Holmes, 1 Cardiovascular Devices Division, University of Ottawa Heart Institute, Ottawa, Ontario, Canada

11:30 AM (104) Waitlist Mortality Risk Among Heart Transplant Candidates by Urgency Status and Ventricular Assist Device (VAD) Use; R.M. Merion, 1 T.E. Hulbert-Shewar, 1 R.T. Bustami, 1 R.A. Wolfe, 1 W.S. Ring, 1 S. Murray, 1 Research, SRTR/University of Michigan, Ann Arbor, MI; 2 Research, SRTR/URREA, Ann Arbor, MI; 3 Surgery, University of Texas Southwestern Medical School, Dallas, TX

11:45 AM (105) Advances in Patient and Economic Outcomes Associated With Left Ventricular Assist Devices for Destination Therapy; K. Nelson, 1 K. Tong, 2 A. Elman, 1 J. Long, 1 Department of Cardiovascular Surgery and Utah Artificial Heart Program, Latter Day Saints Hospital, Salt Lake City, UT; 2 Division of Outcomes Research, Quorum Consulting, Inc., San Francisco, CA

10:30 AM-NOON
CONCURRENT SESSION 14
Post Transplant Infectious Disease: Old and New Viruses (Salon ABF)
Moderators: Kate Gould, MB, BS and TBD

10:30 AM (106) Use of the Multi Combination Bactericidal Test To Detect Optimal Antimicrobial Combinations for the Treatment of Pseudomonas Aeruginosa and Burkholderia Cepacia in Patients Undergoing Lung Transplantation; L. Archer, 1 K. Morris, 1 J.D. Perry, 1 J.H. Dark, 2 P.A. Corris, 2 F.K. Gould, 1 Microbiology Department, Freeman Hospital; 2 Applied Immunology and Transplantation Group, Freeman Hospital, Newcastle upon Tyne, United Kingdom

10:45 AM (112) Repertaxin, a Novel IL-8 Receptor Inhibitor, Ameliorates Ischemia-Reperfusion Injury After Experimental Lung Transplantation; S. Dharmarajan, 1 M. Hayama, 1 T. Ishiyama, 1 M. Okazaki, 1 J. Kim, 1 A.S. Krunick, 1 D. Kreisel, 1 G.A. Patterson, 1 2Department of Surgery, Washington University School of Medicine, St. Louis, MO

10:45 AM (113) Dynamic Changes in Cytokine Gene Expression During Cold Ischemia Predicts Outcome After Lung Transplantation in Humans; H. Kaneda, 2 T.K. Waddell, 1 M. Liu, 1 S. Keshavjee, 1 Thoracic Surgery Research Laboratory, Toronto General Hospital, Research Institute, Toronto, Ontario, Canada

11:00 AM (108) Intravenous Ribavirin Is a Safe and Cost-Effective Treatment for Respiratory Syncytial Virus Infection After Lung Transplantation; A.R. Glanville, 1 C.L. Aboyoun, 1 M.L. Plit, 1 M.A. Malouf, 1 2The Lung Transplant Unit, St Vincent’s Hospital, Sydney, NSW, Australia

11:15 AM (109) Hepatitis B Vaccination in Heart Transplant Candidates; W.Q. Foster, 1 A. Murphy, 1 D.J. Vega, 1 W.M. Book, 1 Internal Medicine, Emory University School of Medicine, Atlanta, GA; 2 Surgery, Emory University School of Medicine, Atlanta, GA

11:30 AM (110) Mortality Associated With Use of Hepatitis C Positive Donors in Alternate List Heart Transplantation; S.D. Russell, 1 G.M. Felder, 1 L. Blue, 1 M.B. Higginbotham, 2 C.A. Milano, 2 Medicine, Duke University Medical Center, Durham, NC; 2 Surgery, Duke University Medical Center, Durham, NC

11:45 AM (111) Human Metapneumovirus - The First Series of a New Virulent Infection in Lung Transplant Recipients; P.M. Hopkins, 1 S.M. Williamson, 1 F.D. Kermeen, 1 E.T. McQueen, 2 T.P. Sloots, 2 K.D. McNeil, 1 M.D. Nissen, 1 2Queensland Heart-Lung Transplant Unit, The Prince Charles Hospital, Brisbane, Queensland, Australia; 2 Clinical Virology Research Unit, Royal Children’s Hospital, Brisbane, Queensland, Australia

10:30 AM-NOON
CONCURRENT SESSION 15
Genes and Cytokines in Lung Reperfusion Injury (Salon E)
Moderators: Marc De Perrot, MD and Bryan F. Meyers, MD

10:30 AM (112) Repertaxin, a Novel IL-8 Receptor Inhibitor, Ameliorates Ischemia-Reperfusion Injury After Experimental Lung Transplantation; S. Dharmarajan, 1 M. Hayama, 1 T. Ishiyama, 1 M. Okazaki, 1 J. Kim, 1 A.S. Krunick, 1 D. Kreisel, 1 G.A. Patterson, 1 2Department of Surgery, Washington University School of Medicine, St. Louis, MO

10:45 AM (113) Dynamic Changes in Cytokine Gene Expression During Cold Ischemia Predicts Outcome After Lung Transplantation in Humans; H. Kaneda, 2 T.K. Waddell, 1 M. Liu, 1 S. Keshavjee, 1 Thoracic Surgery Research Laboratory, Toronto General Hospital Research Institute, Toronto, Ontario, Canada

11:00 AM (114) Gene Expression Profiling of Donor Lungs Identifies a Gene Signature Associated With Ischemia-Reperfusion Injury; S. Dharmarajan, 1 M. Hayama, 1 A. Polpitya, 1 T. Ishiyama, 1 M. Okazaki, 1 J. Kim, 1 A.S. Krunick, 1 D. Kreisel, 1 J.P. Cobb, 1 M.A. Watson, 1 G.A. Patterson, 1 2Department of Surgery, Washington University School of Medicine, St. Louis, MO
11:15 AM (115) Early Hemodynamic Lung Injury During Donor Brain Death Enhances Reperfusion Injury
After Lung Transplantation; V.S. Avlonitis, 1 J.A. Kirby, 1 J.H. Dark, 1 School of Surgical and Reproductive
Sciences, University of Newcastle, Newcastle upon Tyne, United Kingdom
11:30 AM (116) Donor Glutathione S-Transferase Genotype Is Associated With Primary Graft Dysfunction
Following Lung Transplantation; J.D. Christie, 1 R. Aplenc, 2 J. DeAndrade, 2 S. Kawut, 2 A. Milstone, 2 A.
Weinacker, 2 L. Zhou, 2 J. Mazzotta, 2 E. DeMissie, 2 E.W. Ely, 2 for the Lung Transplant Outcome Group,
1Pulmonary Medicine, University of Pennsylvania, Philadelphia, PA; 2Pulmonary Medicine, University of
Alabama Birmingham, Birmingham, AL; 3Pulmonary Medicine, Columbia University, NY, NY; 4Pulmonary
Medicine, Vanderbilt University, Nashville, TN; 5Pulmonary Medicine, Stanford University, Palo Alto, CA
11:45 AM (117) Rapid Donor Lung Analysis in Humans Lung Transplantation With Quantitative Multiplex
Rapid RT-PCR Assay; H. Kaneda, 1 X. Bai, 2 T.K. Waddell, 2 M. Liu, 3 S. Keshavjee, 3 Thoracic Surgery
Research Laboratory, Toronto General Hospital, Toronto, Ontario, Canada

10:30 AM-NOON
CONCURRENT SESSION 16
Novel Immunosuppressive Strategies in Lung Transplantation (Salon CD)
Moderators: Andres Varella, MD and Gregory I. Snell, FRACP, MBBS

10:30 AM (118) Randomised Trial of Cyclosporin C0 vs. C2 Monitoring in De Novo Lung Transplant Recipients: Interim Results; J. Cornelissen, 1 A. Wood, 2 S. Pasupathy-Rajah, 2 A. Trull, 2 J. Wallwork, 2
1Clinical Pharmacology, Papworth Hospital NHS Trust, Cambridge, United Kingdom; 2MRC Biostatistics
Unit, Cambridge, United Kingdom; 3Transplant Unit, Papworth Hospital NHS Trust, Cambridge, United
Kingdom
10:45 AM (119) A Randomized Control Trial of Daclizumab vs. Anti-Thymocyte Globulin Induction for Lung Transplantation; J.C. Mullen, 1 A. Dueck, 1 M.J. Bentley, 1 D.L. Modry, 3 K. Stewart, 1 D.C. Lien, 3 P.F.
Halloran, 3 University of Alberta, Edmonton, Alberta, Canada
11:00 AM (120) Rabbit Antithymocyte Globulin Induction Therapy for Lung Transplantation Does Not Affect Long-Term Allograft Function or Survival; M.G. Hartwig, 1 L.D. Snyder, 1 J.Z. Appel, 1 S. Simsir, 2 S.S.
Lin, 2 S.M. Palmer, 2 R.D. Davis, 2 Department of Surgery, Duke University, Durham, NC; 3Department of
Medicine, Duke University, Durham, NC
11:15 AM (121) One Year Complete Follow-Up of a Prospective Randomized International Investigator
Driven Study Comparing Tac and CsA (+ MMF / Steroids) After Lung Transplantation in 274 Patients; H.
Reichenspurner, 1 A. Glanville, 2 W. Klepetko, 2 R. Lama, 2 G.M. Verleden, 2 C. Bravo, 2 M. Estenne, 2 S. Hift, 2
F.Z. Goni, 2 J. Aubert, 2 J.M. Borro, 2 P. Usetti, 3 T. Wahlers, 3 C. Aboyoun, 2 H. Treede, 3 Department of
Cardiovascular Surgery, University Hospital Hamburg-Eppendorf, Hamburg, Germany; 4Alfred Hospital, University of Sydney, Sydney, Australia; 5University of Vienna, Vienna, Austria; 6University of Cordoba, Cordoba, Spain; 7University of Leuven, Leuven, Belgium; 8University of Barcelona, Barcelona, Spain; 9University of Bruxelles, Bruxelles, Belgium; 10University of Kiel, Kiel, Germany; 11University of Santander, Santander, Spain; 12University of Lausanne, Lausanne, Switzerland; 13University of La Coruna, La Coruna, Spain; 14University of Madrid, Madrid, Spain; 15University of Jena, Jena, Germany
11:30 AM (122) Safety of EBV DNA Guided Reduction of Immunosuppression After Lung Transplantation;
E. Verschuuren, 1 A. de Haan, 2 B. Hepkema, 2 M. Erasmus, 3 J. Prop, 2 W. Timens, 2 G. Koeter, 1 W. van der
Bij, 1 Pulmonaryology, University Hospital, Groningen, Netherlands; 2Pathology and Medical Biology,
University Hospital, Groningen, Netherlands; 3Cardiothoracic Surgery, University Hospital, Groningen,
Netherlands
11:45 AM (123) Long-Term Follow Up of a Double-Blind, Randomized, Placebo-Controlled Trial of Cyclosporine Inhalation Solution (CyIS) in Lung Transplant Recipients; A. Iacono, 1 W. Capra, 1 S.
Shrewsbury, 1 B. Johnson, 2 W. Grurgich, 2 T. Corcoran, 1 J. Youssef, 1 D. Smith-Seiler, 1 G. Smaldone, 1 A. Zeevi,
1S. Yousem, 1 J. Fung, 1 J. Dauber, 2 G. Burchart, 1 K. McCurry, 1 B. Griffith, Pulmonary Transplantation/Pulmonary Critical Care, University of Pittsburgh, Pittsburgh, PA; Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, PA

NOON–12:15 PM
Annual Business Meeting (Members only) (Salon G-L)

12:15 PM–2:00 PM
ISHLT Editorial Board Meeting (Rooms 401-402)

12:15 PM-1:45 PM
(Salon ABF)
Supported by an Educational Grant from Roche
Moderators: Jay A. Fishman, MD and Martin Zamora, MD
12:15 PM What is the Current Role of CMV Prophylaxis? Jim J. Egan, MD, Mater Misericordiae Hospital, Dublin, Ireland
12:35 PM Community Acquired Respiratory Viruses, Atul Humar, MD, Toronto General Hospital, Toronto, Canada
12:50 PM Donor Issues: How Do You Handle Hepatitis B and C Positive Donors? Robin Avery, MD, Cleveland Clinic, Cleveland, OH
1:10 PM Challenge of PTLD: Answers from EBV and Xenotransplantation, Jay A. Fishman, MD, Massachusetts General Hospital, Boston, MA
1:30 PM Discussion

12:30 PM – 1:30 PM
MINI-ORAL POSTER PRESENTATION SESSION 3 (Salon E)
Moderators: Bruce R. Rosengard, MD and Joren C. Madsen, MD

12:30 PM (124) Cyclic Strain of Adult Stem Cells Modulates Matrix Metalloproteinase Activity: Mechanism for Promoting Cell-Based Cardiac Remodeling; P.B. Bolno, A.S. Wechsler, S. Ranjgappa, J.Y Kresh, Department of Cardiopulmonary Physiology, Drexel University College of Medicine, Philadelphia, PA
12:35 PM (125) Does Stem Cell Therapy for Ischemic Cardiomyopathy Result in the Improvement of Congestive Heart Failure: A Prospective Randomized Study; A.N. Patel, L. Geffen, R.F. Vina, H.C. Urschel, M. Mathier, R.L. Kormos, F. Benetti, Cardiac Surgery, University of Pittsburgh, Pittsburgh, PA; Benetti Foundation, Rosario, Argentina; Baylor University Medical Center, Dallas, TX
12:40 PM (126) Bioartificial Tissue Grafts Improve Left Ventricular Function in Ischemic Rat Hearts; I. Kutschka, T. Kofidis, I.Y. Chen, A.Y. Sheikh, J. Pearl, S.L. Hendry, G. Hoyt, D.R. Lebl, R.C. Robbins, Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA; Department of Radiology, Stanford University School of Medicine, Stanford, CA
12:45 PM (127) (alpha)-gal Induces Monocyte (beta)-2 Integrin Activation and Firm Adhesion on ICAM-1; D. Modersohn, D. Holinski, H. Schaefer, H. Reichenspurner, Cardiothoracic Surgery, Univeristy of Pittsburgh, Pittsburgh, PA; Pathology, University Hospital, Hamburg, Germany
12:50 PM (128) CD154 and CD28/B7 Costimulation Pathways Regulate Both Natural and Induced Anti-Pig Antibodies in Baboons; G. Wu, 12:55 PM (129) Benefits of Cardiac Resynchronization Therapy (CRT) in Patients With Advanced Congestive Heart Failure Listed for Heart Transplant; F. Oliva, A. Juhász-Nagy, 1 A. Kishida, 2 A. Laaris, H. Zhou, Q. Feng, A. Azimzadeh, R.N. Pierson III, Division of Cardiac Surgery, University of Maryland and Baltimore VA Medical Center, Baltimore, MD
12:55 PM (129) Benefits of Cardiac Resynchronization Therapy (CRT) in Patients With Advanced Congestive Heart Failure Listed for Heart Transplant; F. Oliva, A. Juhász-Nagy, 1 A. Kishida, 2 A. Laaris, H. Zhou, Q. Feng, A. Azimzadeh, R.N. Pierson III, Division of Cardiac Surgery, University of Maryland and Baltimore VA Medical Center, Baltimore, MD
1:00 PM (130) Static Cardiomyoplasty with Synthetic Elastic Net Suppresses Ventricular Dilatation and Dysfunction After Myocardial Infarction in the Rat; A.T. Kawaguchi, 1 F. Oliva, 2 A. Juhász-Nagy, 1 A. Kishida, 2 A. Laaris, H. Zhou, Q. Feng, A. Azimzadeh, R.N. Pierson III, Division of Cardiac Surgery, University of Maryland and Baltimore VA Medical Center, Baltimore, MD
1:10 PM (132) Influence of Viral Infection in the Murine Orthotopic Tracheal Transplantation Model in the Development of Obliterative Airway Disease (OAD); E.Y Kuo, 1 M.J. Walter, 1 W. Chapman, 1 T. Kofidis, 2 T. Yamaoka, 3 Cardiovascular Surgery, Tokai University, Isehara, Kanagawa, Japan; 1 Tokyo Medical and Dental University, Tokyo, Japan; 3 Kyoto Institute of Technology, Kyoto, Japan
1:15 PM (133) Age Dependent Rejection After Heterotopic Experimental Heart Transplantation; S. Holinski, D. Modersohn, C. Proch, R. Meyer, W. Konertz, Department of Cardiovascular Surgery, Charite-University-Hospital, Berlin, Germany; 3 Department of Pathology, German-Heart-Center, Berlin, Germany
1:20 PM (134) Immunosuppression With FK778 and Tacrolimus Prevents the Development of Posttransplant Obliterative Airway Disease; T. Deuse, S. Schreper, F. Koch-Nolte, M. Haddad, E. Schwedhelm, R. Boeger, H. Schaefer, H. Reichenspurner, Cardiovascular Surgery, University Hospital, Hamburg, Germany; Immunology, University Hospital, Hamburg, Germany;
1:30 PM – 1:30 PM
MINI-ORAL POSTER PRESENTATION SESSION 4 (Salon CD)

Moderators: Stephan Schueler, MD and Donald S. Esmore, MD

12:30 PM (136) Neutrophilia Is an Inflammatory Signature of Chronic Heart Failure Modulated by Left Ventricular Assist Devices (VAD); H. Tsukui, A.N. Vallejo, A.N. Patel, R.L. Kormos, Surgery, McGowan Institute for Regenerative Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA; Pediatrics and Immunology, University of Pittsburgh, Pittsburgh, PA

12:35 PM (137) Incidence of Reoperation To Repair / Replace the Novacor LVAS; G. Faggian, J.A. Elefteriades, R. Hetzer, D.S. Esmore, H. Matsuda, R.N. Pierson III, Cardiac Surgery, University Hospital, Verona, Italy; Cardiothoracic Surgery, Yale University School of Medicine, New Haven, CT; Cardiothoracic Surgery, German Heart Center, Berlin, Germany; Cardiothoracic Surgery, Alfred Hospital, Melbourne, Australia; First Department Surgery, Osaka University Medical School, Osaka, Japan; Cardiothoracic Surgery, University of Maryland Medical Center, Baltimore, MD

12:40 PM (138) Clinical Durability of the LionHeart™ Left Ventricular Assist Device (LVAD); Comparison to Bench Testing and Implications for Future Designs; J.P. Boehmer, W.E. Pae, J.P. Lewis, A.J. Snyder, W.J. Eisen, G. Rosenzweig, Surgery, Penn State College of Medicine, Hershey, PA; Arrow, Intl., Reading, PA

12:45 PM (139) Risk Factor Analysis for Bridge to Transplantation with the Cardiowest TAH; J.G. Copeland, R.G. Smith, F.A. Arabia, P.E. Nolan, M.J. Slepian, Sarver Heart Center, University of Arizona, Tucson, AZ


1:00 PM (142) Evaluation of Cyclosporin (CsA) Profiles Month 2 to 6 in an International Phase III Randomized, Multicenter, Double-Blind Study of Everolimus in De Novo Heart Transplant Recipients; H.J. Eisen, D. Mancini, M. Vignano, J. Kobashigawa, School of Medicine, Temple University, Philadelphia, PA; Department of Medicine, Columbia Presbyterian Medical Center, New York, NY; IRCCS, Policlinico San Matteo, Pavia, Italy; Division of Cardiology, University of California at Los Angeles Medical Center, Los Angeles, CA


1:10 PM (144) Biologic Activity of CsA in Cardiac Allograft Recipients Can Be Monitored by Measuring Suppression of NFAT-Regulated Gene Expression; M.H. Konstandin, M. Schoels, R. Klingenberg, T. Giese, T.J. Dengler, Department of Cardiology, University of Heidelberg, Heidelberg, Germany; Institut of Immunology, University of Heidelberg, Heidelberg, Germany

1:15 PM (145) Comparison of Sublingual to Oral Tacrolimus Administration in Lung Transplantation; R.J. Jones, T.A. Bouchousse, B. Eelnaert, E.R. Garrity, J. Villanueva, Pulmonary and Critical Care Medicine, Loyola University Medical Center, Maywood, IL; Preventive Medicine and Epidemiology, Nephrology, Loyola University Medical Center, Maywood, IL; Pharmacology, Loyola University Medical Center, Maywood, IL; Thoracic and Cardiovascular Surgery, Loyola University Medical Center, Maywood, IL

1:20 PM (146) The Feasibility of Complete Withdrawal of Oral Corticosteroids Following Lung Transplantation; P.A. Corris, A.J. Fisher, R. Rutherford, J. Lordan, Applied Immunology and Transplantation Group, University of Newcastle, Newcastle upon Tyne, Tyne and Wear, United Kingdom

2:00 PM-3:30 PM

CONCURRENT SESSION 17

Facing the Nemesis: Cardiac Transplant Vasculopathy (Salon G-L)

Moderators: David Taylor, MD and James K. Kirklin, MD

2:00 PM (147) Influence of Donor Transmitted Atherosclerosis on the Development of Cardiac Allograft Vasculopathy; H. Li, K. Tanaka, H. Anzai, B. Oeser, J. Kobashigawa, J.M. Tobis, Cardiology, University of California at Los Angeles, Los Angeles, CA

2:15 PM (148) The Risk of Cardiac Death in Heart Transplant Recipients With and Without Angiographically Detected Coronary Vasculopathy; K. Lietz, J.M. Herre, Cardiovascular Division, Eastern Virginia Medical School, Norfolk, VA; Sentara Cardiovascular Research Institute, Norfolk, VA

2:30 PM (149) Blood Glutathione as a Marker of Cardiac Allograft Vasculopathy in Heart Transplant Recipients;
2:00 PM-3:30 PM
CONCURRENT SESSION 18
Immunosuppression and Rejection in Lung Transplantation (Salon ABF)

Moderators: Murali M. Chakinala, MD and Jonathan B. Orens, MD

2:00 PM (153) Six Month Results of Sirolimus Versus Azathioprine in a Tacrolimus Based Immunosuppressive Regimen in Lung Transplantation; S.M. Bhurade, V. Ahya, R. Kotloff, M. Baz, V. Valentine, S. Arcasoy, R. Love, W.T. Vigneswaran, E.R. Garrity, Medicine, Loyola University Medical Center, Maywood, IL; Medicine, University of Pennsylvania, Philadelphia, PA; Medicine, University of Florida, Gainesville, FL; Medicine, Ochsner Transplant Center, New Orleans, LA; Medicine, Columbia University, New York, NY; Cardiovascular Surgery, University of Wisconsin, Madison, WI


2:30 PM (155) Differences in Survival and De Novo Anti-Donor Antibody Development Among Lung Transplant Recipients Presensitized to Third Party Class I and Class II HLA Antigens; J.Z. Appel, M.G. Hartwig, E. Cantu, S.M. Palmer, N.L. Reinsmoen, R.D. Davis, Lung Transplant Program, Duke University Medical Center, Durham, NC

2:45 PM (156) Subendothelial C4d Deposition and Intragraft B Cell Infiltrates Are Associated With High-Grade Acute Rejection in Lung Transplantation; A.L. Girnita, D.N. Iconescu, S.A. Yousem, D. Zaldonis, K.R. McCurry, A. Zeevi, Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA

3:00 PM (157) Tacrolimus in Lung Transplantation: New Strategies To Optimize Dose; R. Ragette, M. Kamler, G. Weinreich, H. Teschler, H. Jakob, Pneumology, Ruhrlandklinik, University Hospital of Essen, Essen, Germany; Thoracic and Cardiovascular Surgery, German Heart Center Essen, University Hospital of Essen, Essen, Germany


2:00 PM-3:30 PM
CONCURRENT SESSION 19
Alternatives to Transplantation (Salon E)

Moderators: Robert C. Robbins, MD and Thomas K. Waddell, MD

2:00 PM (159) Transplantation of Fk1-Positive Embryonic Stem Cells Improves Cardiac Function After Acute Myocardial Infarction in Mice; H. Nakajima, S. Baba, G.U. Premaratne, X. Lin, N. Kanemitsu, K. Tambara, T. Ikeda, T. Nakahata, M. Komeda, Cardiovascular Surgery, Kyoto University, Kyoto, Japan; Pediatrics, Kyoto University, Kyoto, Japan

2:15 PM (160) No Evidence for Cardiac Differentiation of Human Endothelial Progenitor Cells After Coculture with Neonatal Rat Cardiomyocytes; I. Gruh, J. Beilner, U. Bloemer, A. Haverich, U. Martin, Leibniz Research Laboratories for Biotechnology and Artificial Organs (LEBAO), Hannover Medical School, Hannover, Germany

2:30 PM (161) Xenogenic Ex Vivo Perfusion of Lungs From GaIT KO Pigs; B.-N. Nguyen, C. Schroder, J.S. Allan, T. Zhang, G. Wu, A.M. Azimzadeh, H.I. Shuurman, D.H. Sachs, R.N. Pierson III,
2:00 PM-3:30 PM
**CONCURRENT SESSION 20**

**Markers of Cardiac Allograft Rejection (Salon CD)**

Moderators: TBD and Michael C. Fishbein, MD

2:00 PM (165) Production of Donor Specific Anti-MHC Class II Antibodies Is Associated With Cardiac Graft Vasculopathy; J.D. Smith, D.J. Anna, F.E. Rachel, P. Ariala, B.R. Nicholas, M. Andrew, M.L. Rose, Transplant Immunology, Royal Brompton and Harefield Hospital, Harefield, Middlesex, United Kingdom; Cardiology Department, Royal Brompton and Harefield Hospital, Harefield, Middlesex, United Kingdom

2:15 PM (166) Phosphorylation of S6 Ribosomal Protein at Serine 235/236 Is a Marker of Human Heart Transplantation; E.J. Lepin, L. Hong, Q.J. Zhang, D.W. Gjertson, J.A. Kobashigawa, M.C. Fishbein, E.F. Reed, Departments of Pathology and Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA

2:30 PM (167) Distinctive Peripheral Blood Gene Expression Profiles in Patients Forming Nodular Endocardial Infiltrates (Quilty Lesions) Following Heart Transplantation; C.C. Marboe, P.G. Lal, K. Chu, J. Wohlgemuth, G. Berry, M. Billingham, Pathology, Columbia University Medical Center, New York, NY; Expression Diagnostics, South San Francisco, CA; Pathology, Stanford University Medical Center, Stanford, CA

2:45 PM (168) Early Growth-Response Factor- 1 Is Involved in Cellular Injury of Transplanted Hearts; D. Abraham, S. Aharinejad, A. Zuckermann, P. Paulus, R. Schaefer, M. Grimm, Cardiovascular Research, Anatomy and Cell Biology, Vienna Medical University, Vienna, Austria; Cardiothoracic Surgery, Vienna Medical University, Vienna, Austria

3:00 PM (169) Vascular Expression of hsp-27 Is Associated with Absence of Graft Vasculopathy After Cardiac Transplantation; M. Rose, A. De Sousa, E. Mc Gregor, R. Wait, A. Mitchell, N. Banner, M. Dunn, National Heart and Lung Institute, Imperial College, Harefield, Middlesex, United Kingdom; Proteome Sciences plc, London, United Kingdom; Kennedy Institute of Rheumatology, Imperial College, London, United Kingdom; Cardiology, Royal Brompton and Harefield Hospitals, Harefield, Middlesex, United Kingdom; Neuroscience Institute of Psychiatry, London, United Kingdom

3:15 PM (170) Humoral Rejection in Human Cardiac Allografts: Examination of Immunoglobulins and Complement Activation Products C4d and C3d; E.R. Rodriguez, D.V. Skojeck, A. Zachary, E.K. Kasper, W.M. Baldwin, Pathology, Johns Hopkins University School of Medicine, Baltimore, MD; Medicine, Johns Hopkins University School of Medicine, Baltimore, MD; Surgery, Johns Hopkins University School of Medicine, Baltimore, MD

3:30 PM-4:00 PM
Coffee Break/View Exhibits/View Posters (Franklin Hall)

4:00 PM-5:30 PM
**CONCURRENT SESSION 21**

**Philip K. Caves Award Candidate Presentations (Salon ABF)**

Moderators: George Tellides, MD and Abbas Ardehali, MD


4:15 PM (172) Bone Marrow Stem Cells Prevent Pps-Transplant Obliterative Airway Disease in Mice; F. D’Imperio, M. Liu, S. Keshavjee, T.K. Waddell, Thoracic Surgery, University of Toronto, Toronto, Ontario, Canada

4:30 PM (173) LVAD Support Severely Affects the Integrity of Myocardial Basement Membranes; A.H. Bruggink, M.F.M. Oosterhout, N. de Jonge, J.P.M. Cleutjens, J. van Kuik, F.H.J. Gmelig-Meyling, Department of Cardiovascular Surgery, Hayama Heart Center, Hayama, Japan
Trulock, R. Hachem, M. Chakinala, G.A. Patterson, N. Moazami, Surgery, Washington University, St Louis, MO

4:45 PM (186) Recurrence of Alpha 1-Antitrypsin Deficiency Emphysema on Computed Tomography (CT) after Lung Transplantation; S.A. Sathyapala, N.K. Gupta, J.-P. Westwood, J. Partridge, M.R. Carby, Transplant Medicine, Harefield Hospital, Royal Brompton & Harefield NHS Trust, Harefield, Middlesex, United Kingdom

5:00 PM (187) Presentation, Treatment and Outcome of 24 Patients with Posttransplant Lymphoproliferative Disorder (PTLD) after Lung Transplantation; J. Misleh, A. Loren, V. Ahya, R. Kotloff, L. Douglas, N. Aqui, D. Tsai, Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA

5:15 PM (188) Resolution of Severe Reperfusion Injury Post Lung Transplantation Following the Administration of Endobronchial Surfactant; F.D. Kermeen, Hopkins Medical Institutions, Baltimore, MD

5:30 PM (189) Sirolimus (SRL) and Its Effects after 12 Month Therapy on Patients With Calzineurin (CNI) Induced Renal Dysfunction; K. Hariri, S. Roedler, D. Dunkler, E. Szent-Ivanyi, A. Aliabadi, M. Grimm, E. Wollner, University Central Hospital, Helsinki, Finland; Alitalo, Ziegenfuss, PA

4:00 PM-5:30 PM

CONCURRENT SESSION 24

Biology of Vascular and Cardiac Allograft Injury (Salon CD)

Moderators: Gerald J. Berry, MD and Michael S. Mulligan, MD

4:00 PM (189) Common Anti-Inflammatory and Diverse Smooth Muscle Cell Effects of AAV-Mediated Angiopoietin-1 and -2 Expression in Rat Cardiac Allografts; A.I. Nykänen, T. Tung, H. Russell, T.J. Dengler, Division of Cardiology, University of Heidelberg, Heidelberg, Germany

4:15 PM (189) Cyclosporine Decreases Vascular Progenitor Cells Following Cardiac Transplantation and Attenuates Progenitor Cell Growth In Vitro; W.R. Davies, S. Wang, K. Oi, N.M. Caplice, C.G.A. McGregor, William J von Liebig Transplant Center, Mayo Clinic, Rochester, MN; Division of Cardiovascular Diseases and Molecular Medicine Program, Mayo Clinic, Rochester, MN

4:30 PM (190) Inflammatory and Pro-Thrombotic Protein Expression Is Induced in Human Vascular Endothelial Cells by Lymphocyte-Associated Light; S. Celik, S. Wang, K.A. Gleissner, A.O. Doesch, M. Konstandin, T.J. Dengler, Division of Cardiology, University of Heidelberg, Heidelberg, Germany

4:45 PM (191) Corticosteroids Enhance Cyclosporine-Induced Vascular Injury: Interactive Effect between Endothelium-1 and Nitric Oxide Bioavailability; D. Ramzy, C. A. Gleissner, A.O. Doesch, M. Konstandin, T.J. Dengler, Division of Cardiology, University of Heidelberg, Heidelberg, Germany

5:00 PM (190) Common Anti-Inflammatory and Diverse Smooth Muscle Cell Effects of AAV-Mediated Angiopoietin-1 and -2 Expression in Rat Cardiac Allografts; A.I. Nykänen, T. Tung, H. Russell, T.J. Dengler, Division of Cardiology, University of Heidelberg, Heidelberg, Germany

5:30 PM-6:30 PM

GENERAL POSTER SESSION/Wine and Cheese Reception (Franklin Hall)


4:00 PM (193) Downreguration of CD8+ T Cell Cytotoxicity Via Perforin/ Granzyme B Pathway Protects Cardiac Allograft Myocytes in Interleukin-4 and -10 Combined Gene Therapy; H. Furukawa, K. Oshima, H. Russell, T. Tung, G. Cui, L. Sen, Surgery, University of California at Los Angeles Medical Center/School of Medicine, Los Angeles, CA

5:15 PM (194) Gene Transfer of the Tryptophan-Catabolizing Enzyme Indolea mine 2,3-Dioxygenase Prolongs Rat Cardiac Allograft Survival; J. Li-Zhong, E. Simeoni, S. Fleury, L.K. von Segesser, G. Vassalli, Cardiology, University of Lausanne Medical Center, Lausanne, Switzerland; Cardiovascular Surgery, University of Lausanne Medical Center, Lausanne, Switzerland; Experimental Surgery, University of Lausanne Medical Center, Lausanne, Switzerland

5:30 PM-6:30 PM
(355) Pregnancy Outcomes in Female Lung Transplant Recipients; L.A. Coscia, C.H. McGrory, M.R. Chotiner, M.J. Moritz, V.T. Armenti, Surgery, Temple University School of Medicine, Philadelphia, PA; "Division of Cardiothoracic Surgery, David Geffen School of Medicine at University of California, Los Angeles, CA; "Division of Pulmonary Medicine, Critical Care and Hospitalists, David Geffen School of Medicine at University of California, Los Angeles, CA

(356) Clinical Outcome Following Concomitant Cardiac Operation at the Time of Lung Transplantation; G.T. Schnickel, D.J. Ross, F. Mitropoulos, S. Lackey, A. Shefizadeh, A. Ardehali, Division of Cardiothoracic Surgery, David Geffen School of Medicine at University of California, Los Angeles, CA; "Division of Pulmonary Medicine, Critical Care and Hospitalists, David Geffen School of Medicine at University of California, Los Angeles, CA

(357) Clinical and Functional Status of Cystic Fibrosis (CF) Heart-Lung Transplant (HLT) Recipients Surviving More Than Ten Years; K.M. Gyi, M.R. Carby, M.E. Hodson, Department of Cystic Fibrosis, Royal Brompton and Harefield NHS Trust, London, United Kingdom; "Department of Transplantation, Royal Brompton and Harefield NHS Trust, Harefield, Middlesex, United Kingdom

(358) Does Perfadex Improve Clinical Outcomes in Lung Transplantation? R.F. Kelly, G.T. Schnickel, D.J. Ross, F. Mitropoulos, S. Lackey, A. Shefizadeh, A. Ardehali, Division of Cardiothoracic Surgery, David Geffen School of Medicine at University of California, Los Angeles, CA; "Division of Pulmonary Medicine, Critical Care and Hospitalists, David Geffen School of Medicine at University of California, Los Angeles, CA


(360) Pharmacokinetics of Mycophenolate and Its Glucuronidated Metabolites in Stable Lung Transplant Recipients; N. Partovi, L. Ting, M.H.H. Ensom, W. Riggs, R.D. Levy, Pharmaceutical Sciences, University of California at Los Angeles, Los Angeles, CA; "Faculty of Medicine, University of British Columbia, Vancouver, Canada


(362) Caution Using a Calcineurin Inhibitor-Free Renal Sparing Protocol for Heart Transplant Patients With Renal Dysfunction; J.K. Patel, J.A. Kobashigawa, A. Marquez, B.T. Oeser, A. Velleca, R. Camara, H. Laks, Cardiology, University of California at Los Angeles, Los Angeles, CA

(363) Doppler Evaluation of Cardiac Allograft Dysfunction in Long-Term Heart Transplantation Recipients With Normal Coronary Angiograms; F. Tona, A.L.P. Cafario, A. Gambino, G. Feltrin, G. Toscano, D. Calzolajr, C. Saraij, O. Paccagnella, A. Vinci, M.G. Leone, A. Angelini, A. Ramondo, G. Thiene, G. Gerosa, S. Iliceto, Cardiology, University of Padova; "Cardiovascular Surgery; "Pathology, University of Padova, Padova, Italy

(364) Usefulness of Mitral Anulus Velocities for Detection of Rejection After Heart Transplantation; K.M. Kraszewski, M. Sobieszcanska, J. Korewicki, P. Hoffman, Department of Adult Congenital Heart Disease, National Institute of Cardiology, Warszawa, Poland; "Department of Heart Failure, National Institute of Cardiology, Warszawa, Poland

(365) Pre Transplant but Not Post Transplant Anemia Is Associated With Reduced One Year Survival After Cardiac Transplantation; A.B. Taegtmeyer, P. Rogers, J.B. Breen, N.R. Banner, P.J. Barton, M.H. Yacoub, Transplant Unit, Harefield Hospital, Harefield, Middlesex, United Kingdom; "Heart Science Centre, Harefield Hospital, Harefield, Middlesex, United Kingdom

(366) Accelerated Naive CD8 T-Cell Homing During Acute Cellular Rejection After Clinical Heart Transplantation; P. Athanasopoulos, L.M.B. Vaessen, A.H.M.M. Balk, A.P.W.M. Maat, A.J.C. Rogers, W. Weimar, Cardiac Surgery, Erasmus MC; "Internal Medicine, Erasmus MC; "Cardiology, Erasmus MC, Rotterdam, Netherlands

(367) Incidence of Cardiac Deaths Due to Circulatory Interventions With Stents in Cardiac Transplant Recipients; F.M. Bader, E.M. Gilbert, A.G. Krouwer, N. Humayun, Y. Al-Saghir, M.E. Hagan, H. Thomas, J.D. Scholnick, D.G. Rennlund, Cardiology, University of Utah, Salt Lake City, UT; "Cardiology, LDS Hospital, Salt Lake City, UT; "Cardiology, George E. Wahlen VA Medical Center, Salt Lake City, UT

(368) Pretransplant QTc Interval Duration Predicts Outcome of Heart Failure Patients Undergoing Cardiac Transplantation; B. Vrtovec, A.P. Yazdanbakhsh, I.D. Gregoric, R. Radovancevic, P.V. Juarez, B. Radovancevic, "Transplant Research, Texas Heart Institute, Houston, TX


(370) The uPA/PAI-1 Molecular Defect in Idiopathic Dilated Cardiomyopathy (DCM) Persists After Cardiac Transplantation; S. Aharinejad, M. Grimm, A. Zuckermann, P. Paulus, R. Schaefner, D. Abraham, Cardiac Surgery, Vienna Medical University, Vienna, Austria; "Cardiovascular Research, Anatomy and Cell Biology, Vienna Medical University, Vienna, Austria

(371) Outcomes of an Alternate List Strategy for Heart Transplantation; M. Felker, C.A. Milano, J.E. Yager, A.F. Hernandez, L. Blue, M.B. Higginbotham, A.J. Lodge, S.D. Russell, Department of Medicine, Duke University Medical Center, Durham, NC; "Department of Surgery, Duke University Medical Center, Durham, NC

(372) Self-Administered Fingerpck Sampling To Determine Cyclosporine C2 Blood Levels in Transplant Patients;
(374) The Role of Pressure-Flow Derived Measurements in the Evaluation of Coronary Physiology of Heart Transplant Recipients; G. Davidavicius, S. Mansour, M. Vanderheyden, B. de Bruyne, F. Wellens, M. Goethals, Cardiology, Cardiovascular Center Aalst, Aalst, Belgium

(375) Impaired Coronary Flow Reserve: A New Noninvasive Predictor of Cardiac Allograft Vasculopathy Severity and Diffusion; F. Tona, A.L.P. Caforio, R. Montisci, C. Sarais, A. Angelini, A. Gambino, G. Toscano, G. Feltrin, D. Galzoli, A. Ramondo, A. Vinci, M.G. Leone, G. Thiene, G. Gerosa, S. Iliceto, Cardiology, University of Padova; Cardiology, University of Cagliari, Cagliari, Italy; Pathology; Cardiovascular Surgery, University of Padova, Padova, Italy

(376) Evaluation of Transplant Coronary Disease in Young Adults; Utility of Myocardial Contrast Echocardiography; L. Lamers, G. Ensing, E. Locriccio, M. Zamberlan, D. Crowley, R. Gajarski, Pediatrics, University of Michigan, Ann Arbor, MI


(378) Erythropoietin Treatment of Anemia Post Heart Transplantation Raises Hemoglobin Levels and Improves Quality of Life; C.A. Gleissner, R.H. Klingenberg, M. Konstandin, S. Celik, T.J. Dengler, Department of Cardiology, University of Heidelberg, Heidelberg, Germany

(379) Cyclosporine Profiling in Heart Transplant Patients: Correlation with Clinical Outcome; J. Barnard, J. Thekkudam, S. Richardson, R. Martytszczuk, M. Bittar, N. Khasati, B. Keevil, N. Yonan, The Transplant Centre, South Manchester University Hospitals NHS Trust, Wythenshawe, Manchester, United Kingdom; Department of Biochemistry, South Manchester University Hospitals NHS Trust, Wythenshawe, Manchester, United Kingdom

(380) Twelve Months Results of Enteric-Coated Mycophenolate Sodium (EC-MPS) in De Novo Heart Transplant Patients Showed Excellent Efficacy and Safety; J.A. Kobashigawa, D.G. Renlund, G. Gerosa, A. Caforio, H. Ross, H.B. Lehmkuhl, H. Eisen, J. Segovia, R. Brambilla, University of California, Los Angeles, CA; Heart Failure Treatment and Prevention, Salt Lake City, UT; Policlinico University Hospital, Padova, Italy; Toronto General Hospital, Toronto, Ontario, Canada; Deutsches Herzzentrum, Berlin, Germany; Temple University Hospital, Philadelphia, PA; Hospital Universitario Puerta de Hierro, Madrid, Spain; Novartis Pharma AG, Basel, Switzerland, for the international CERL080A2401 study group

(381) Everolimus (Certican) in Heart Transplantation – Early Experience; H. Lehmkuhl, M. Hummel, M. Dandel, O. Grauhan, C. Knosalla, R. Hetzer, Department of Heart, Thoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany

(382) Negative Association between CMV-Viraemia and Bronchiolitis Obliterans Syndrome in Lung Transplant Recipients; I.A. Forrest, A. Krause, P.A. Corris, J.H. Dark, F.K. Gould, Applied Immunobiology and Transplantation Group, University of Newcastle upon Tyne and Freeman Hospital, Newcastle upon Tyne, United Kingdom; Department of Medical Microbiology, Freeman Hospital, Newcastle upon Tyne, United Kingdom

(383) Sirolimus-Associated Thrombotic Thrombocytopenic Purpura (TTP): Report of Three Cases and Review of the Literature; A.E. Eyzaguirre, R.B. Love, D.A. Hargate, R. Schilz, Pulmonary and Critical Care Medicine, University Hospitals of Cleveland, Cleveland, OH; Cardiothoracic Surgery, University of Wisconsin, Madison, WI

(384) Tricuspid Valve Replacement After Cardiac Transplantation; R. Alharethi, F.M. Bader, A.G. Kfoury, E.M. Gilbert, D.G. Renlund, Cardiology, LDS Hospital, Salt Lake City, UT; Cardiology, University of Utah, Salt Lake City, UT

(385) Early Experience with Ezetimibe in the Management of Hyperlipidemia Post-Cardiac Transplant; S.A. Virani, C. Imai, K.H. Humphries, J. Frolich, A. Ignaszewski, Division of Cardiology, University of British Columbia; Department of Pathology, University of British Columbia, Vancouver, Canada

(386) Percutaneous Coronary Intervention With Stent Deployment for the Treatment of Graft Vasculopathy After Cardiac Transplantation- A Single Center Experience; B. Sheick-Yousif, J. Lavee, Y. Har Zahav, Heart Transplantation Unit, Department of Cardiac Surgery, Sheba Medical Center, Tel Hashomer, Israel; Heart Institute, Sheba Medical Center, Tel Hashomer, Israel

(387) Validation of Algorithm for Diagnosis and Treatment of Cytomegalovirus (CMV) Infection in Heart Transplant Recipients Based of pp65 Antigenaemia by Quantitative Polymerase Chain Reaction (PCR); M.W. Zakliczynski, S. Dworniczak, U. Mazurek, M. Zembala, Department of Transplantation, Silesian Center for Heart Disease, Zabrze, Poland

(388) Successful Outcome Following Lung Transplantation for Recipients Colonised With Filamentous Fungi at Time of Transplant; D.A. Wearmouth, L. Archer, P.A. Corris, J.H. Dark, F.K. Gould, Applied Immunobiology and Transplantation Group, Freeman Hospital, Newcastle upon Tyne, United Kingdom; Applied Immunobiology and Transplantation Group, Freeman Hospital, Newcastle upon Tyne, United Kingdom
Review of Patient Outcomes of Aspergillus Prophylaxis With Voriconazole After Lung Transplantation; J.B. Lehneman, G.A. Smallwood, L.A. Lesniak, E.C. Lawrence, Center for Transplantation, Emory University Hospital, Atlanta, GA; Department of Pharmacy, Emory University Hospital, Atlanta, GA; McKelvey Lung Transplantation Center, Emory University Hospital, Atlanta, GA

Clostridium Difficile Colitis after Lung Transplantation: The Role of Routine Prophylaxis; A. Bertani, S. Husain, K.R. McCurry, A. Boujoukos, Department of Thoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA; Department of Infectious Disease, University of Pittsburgh Medical Center, Pittsburgh, PA; Department of Critical Care, University of Pittsburgh Medical Center, Pittsburgh, PA

Risk Factors for Perioperative Mortality and Nosocomial Infections in Lung Transplantation; F. Mattner, S. Fischer, H. Weissbrodt, A.R. Simon, P. Struckmeier, J. Gottlieb, T. Welte, P. Gastmeier, M. Strueber, Medical Microbiology and Hospital Epidemiology, Hannover Medical School, Hannover, Germany; Department of Thoracic Surgery, Hannover Medical School, Hannover, Germany; Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany

Mucociliary Clearance Following Lung Transplantation Is Impaired and Improves With Acute Albuterol Inhalation; B.L. Laube, Y.J. Karmazyn, J.B. Orens, P.J. Mogayzel, Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, MD

7:45 AM Invited Lecture: Toward Clinical Tolerance, Christian Larsen, MD, Emory University, Atlanta, GA
8:15 AM (195) Featured Abstract Presentation: Effect of Immunosuppression on Foxp3 Expression In Vitro and In Vivo after Clinical Heart Transplantation; C.C. Baan,1 B.J. van der Mast,1 A.M.A. Peeters,1 S.S. Korevaar,1 A.H.M.M. Balk,2 W. Weimar,1 1Internal Medicine, Erasmus MC; 2Cardiology, Erasmus MC, Rotterdam, Netherlands
8:25 AM (196) Featured Abstract Presentation: Generation of CD8+CD28 T Suppressor Cells in Heart Transplant Recipients; S. Galluzzo,1 A.J. Naiyer,1 J. Manavalan,1 L. Scoatto,1 S. Kim-Shulze,1 D. Mancini,1 R. Cortesini,1 N. Suciu-Foca,1 1Department of Pathology, Columbia University, New York, NY
8:35 AM Invited Lecture: Clinical Neonatal Tolerance, Lori J. West, MD, DPhil, Hospital for Sick Children, Toronto, Canada
8:55 AM Invited Lecture: Regulatory T-Cells, Professor Herman Waldmann, Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom

9:30 AM-9:45 AM Coffee Break (Ballroom Foyer)
9:45 AM-11:15 AM CONCURRENT SESSION 25 Myocardial Recovery: Myth or Magic (Salons G-L)
Moderators: Srinivas Murali, MD and Roland Hetzer, MD, PhD

9:45 AM (197) Changes of the Collagen Composition in the Heart Induced by Microcurrent Application. A Future Approach to Heart Failure Treatment? J. Mueller,1 B. Kapeller,1 G. Wallukat,1 K. Macfeld,2 1Research, Berlin Heart, Berlin, Germany; 2Institute of Biomedical Research, Vienna, Austria
10:00 AM (198) Long-Term Outcome in Patients With Idiopathic Dilated Cardiomyopathy After Weaning From Left Ventricular Assist Devices; M. Dandel,1 Y. Weng,1 H. Siniawski,1 E. Potapov,1 R. Hetzer,1 1Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany
10:15 AM (199) Maximal Oxygen Uptake Improvement With Long-Term LVAD Support; J.C. Matthews,1 F.D. Pagani,1 S. Wright,2 M. Daly-Myers,2 D.B. Dyke,1 1Division of Cardiovascular Medicine, The University of Michigan, Ann Arbor, MI; 2Section of Adult Cardiac Surgery, The University of Michigan, Ann Arbor, MI
10:30 AM (200) Improvement of Sympathetic Nerve Activity Rather Than Myocardial Fibrosis May Contribute to Functional Recovery of Idiopathic Cardiomyopathy During Prolonged Mecanical Ventricular Support; G. Matsumiya,1 O. Monta,1 Y. Sawá,1 N. Fukushima,1 H. Matsuda,1 Department of Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
10:45 AM (201) Evaluation of Serum Markers in Heart Failure: Study in Heart Transplant and Assist Device Candidates; S. Buz,1 N. Qedra,1 F. Wagner,1 C. Knausia,1 M. Pasic,1 Y. Weng,1 R. Hetzer,1 1Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany
11:00 AM (202) Five-Year Experience With Driving Privileges for LVAD Patients; W.H. Perry,2 A.L. Eccles,1 A.H. Healy,1 C.R. Wecker,1 K.E. Nelson,1 K.A. McCloy,1 R. Khodaverdian,1 J.W. Long,1 Utah Artificial Heart Program, LDS Hospital, Salt Lake City, UT

9:45 AM-11:15 AM CONCURRENT SESSION 26 Post Transplant Infectious Disease: Fungi, Myobacteria and More (Salon ABF)
Moderators: Shahid Husain, MD and Robert D. Levy, MD

9:45 AM (203) Nebulized Liposomal Amphotericin B (n-LAB) Prophylaxis for Aspergillus Infection in Lung Transplantation (LT): Pharmaokinetics, Safety and Efficacy; V. Monforte,1 A. Roman,1 J. Gavaldà,2 P. Usseti,1 R. Lopez,1 C. Bravo,1 L. Pou,1 1Pneumology, Hospital Vall d'Hebron, Barcelona, Spain; 2Infectious Diseases, Hospital Vall d'Hebron, Barcelona, Spain; 3Pneumology, Clínica Puerta de Hierro, Madrid, Spain; 4Biochemistry, Hospital Universitari Vall d'Hebron, Barcelona, Spain
10:00 AM (204) Intrapulmonary Penetration of Voriconazole in Lung Transplant Patients; B. Capitano,1 B.A. Potoski,2 S. Husain,1 S. Zhang,1 D.L. Paterson,1 S.M. Studer,1 K.R. McCurry,1 R. Venkataramanan,1 1School of Pharm., University of Pittsburgh, Pittsburgh, PA; 2Division of Infectious Disease, University of Pittsburgh, Pittsburgh, PA; 3Division of Pulmonary and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA
10:15 AM (205) A Retrospective Comparison of Aerosolized Amphotericin B Deoxycholate to Aerosolized Amphotericin B Lipid Complex in Preventing Invasive Aspergillosis in Lung Transplant Recipients; L. Drozhinin,1 P. Chin-Hong,1 C. Hoopes,2 J. Golden,1 S. Hays,1 Pulmonary and Critical Care, University of...
California, San Francisco, San Francisco, CA; 2Thoracic Surgery, University of California, San Francisco, San Francisco, CA; 3Infectious Disease, University of California, San Francisco, San Francisco, CA
10:30 AM (206) Infectious Complications at Six Months in Lung Transplant Recipients Undergoing Pretransplant T-Cell Depletion With Alemtuzumab; S. Husain,1 S. Studer,2 D.L. Paterson,1 D.B. Zaldonis,3 E.J. Kwak,1 K.R. McCurry,1 Infectious Disease, University of Pittsburgh, Pittsburgh, PA; 2Pulmonary and Critical Care; 3Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA
10:45 AM (207) Isolation of Atypical Mycobacteria in Lung and Heart-Lung Transplant Recipients; K. Thaning, N. Roy, A.V. Hall, M.E. Hodson, M.R. Carby, Transplant Medicine, Harefield Hospital, Middlesex, United Kingdom; Respiratory Medicine, Royal Brompton Hospital, London, United Kingdom
11:00 AM (208) An International Survey of Mycobacterium Abscessus Infections in Lung Transplant Recipients; S.M. Chernenko,1 A. Hamar,1 C. Chaparro,1 M.A. Hutchison,1 S. Keshavjee,2 L.G. Singer,1 Toronto Lung Transplant Program, Toronto General Hospital, Toronto, Ontario, Canada

9:45 AM-11:15 AM
CONCURRENT SESSION 27
New Insights in Heart Failure Prognosis (Salon E)
Moderators: Mariell Jessup, MD and Hans-Ulrich Stempfle, MD
9:45 AM (209) Prognostic Survival Scores in Patients Referred for Cardiac Transplantation; A.B. Taegtmeyer,1 I.A. Bolad,2 S.J. Bond,2 S. Bentzen,2 A.M. Crook,1 N.R. Banner,1 Transplant Unit, Harefield Hospital, London, United Kingdom; 2Biostatistics Department, Mount Vernon Hospital, London, United Kingdom
10:00 AM (210) Early Recovery Cardiopulmonary Parameters after Exercise Testing as Predictors of Mortality in CHF Patients; S. Dimopoulos,1 M. Anagnostiou-Nana,1 D. Sakellariou,1 S. Kapsimalakou,1 P. Roditis,1 K. Kritikos,1 S. Gyftopoulos,1 S. Nanas,1 C. Roussos,1 Pulmonary and Critical Care Medicine, University of Athens, Greece; 2Clinical Therapeutics, University of Athens, Greece
10:15 AM (211) Elevated B-Type Natriuretic Peptide Is Associated With Ventricular Tachyarrhythmic Events Determined by ICD Interrogation in Congestive Heart Failure Patients; R. Klingenberg,1 R. Becker,1 D. Schellberg,1 G. Heinze,1 R. Kell,1 A. Remppis,1 W. Schoels,1 H.A. Katus,1 T.J. Dangler,1 1Cardiology, Hospital University Heidelberg, Heidelberg, Germany; 2Section of Clinical Biometrics, University of Vienna, Vienna, Austria
10:30 AM (212) Effects of Gender on Peak Oxygen Consumption and the Timing of Cardiac Transplantation; S. Elmariah,1 L.R. Goldberg,1 M.T. Allen,1 A. Kao,1 Department of Medicine, Division of Cardiology, Hospital of the University of Pennsylvania, Philadelphia, PA; 2Mid-America Heart Institute, Kansas City, MO
10:45 AM (213) Permanent Pacing Is a Risk Factor for the Development of Heart Failure: A Statewide Study; R.S. Freudenberger,1 A.C. Wilson,1 J.K. Kirklin,2 S.T. Treves,1 L.B. Armsby,2 R.R. Thigyarajan,1 J.E. Mayer Jr.,1 L.B. Smoot,1 S.T. Treves,1 E.D. Blume,1 Cardiovascular Surgery, Childrens Hospital Boston, Boston, MA; 2Cardiology, Childrens Hospital Boston, Boston, MA; 3Nuclear Medicine, Childrens Hospital Boston, Boston, MA
11:00 AM (214) Racial Differences in Peak VO2 and Survival in Heart Failure Patients; S. Elmariah,1 L.R. Goldberg,1 M.T. Allen,1 A. Kao,1 Department of Medicine, Division of Cardiology, University of Pennsylvania, Philadelphia, PA; 2Mid America Heart Institute, Kansas City, MO

9:45 AM-11:15 AM
CONCURRENT SESSION 28
Long Term Concerns and Complications after Pediatric Thoracic Transplantation (Salon CD)
Moderators: Anne I. Dipchand, MD and Stuart C. Sweet, MD, PhD
9:45 AM (215) Myocardial Perfusion SPECT With 99mTc-MIBI in Coronary Vasculopathy Following Pediatric Heart Transplantation; K.J. Guleserian,1 L.B. Armsby,2 R.R. Thiagarajan,1 J.E. Mayer Jr.,1 L.B. Smoot,1 S.T. Treves,1 E.D. Blume,1 Cardiovascular Surgery, Childrens Hospital Boston, Boston, MA; 2Cardiology, Childrens Hospital Boston, Boston, MA; 3Nuclear Medicine, Childrens Hospital Boston, Boston, MA
10:00 AM (216) Development and Significance of Late Dystolic Dysfunction in Pediatric Heart Transplant Patients; V.B. Sivarajan,1 J. Acampora,1 B.J. Clark II,1 J.W. Gaynor,1 B.D. Hanna,1 S.M. Paridon,1 T.L. Spray,1 G. Wernovsky,1 H. Zhao,1 M.R.K. Chrisant,1 ‘Division of Cardiology, Childrens Hospital of Philadelphia, Philadelphia, PA
10:15 AM (217) Adjunctive Mycophenolate vs. Azathioprine for Prevention of Rejection in Pediatric Heart Transplant Recipients; W.R. Morrow,1 J.G. Parker,1 D.C. Naftel,2 S. Mital,3 C.C. Canter,4 J.J. Drummond-Webb,1 I.H. Kajevska,1 J.C. Bryant,1 J.K. Kirklin,2 Pediatrics and Surgery, University of Arkansas for Medical Sciences, Little Rock, AR; 1Surgery, University of Alabama at Birmingham, Birmingham, AL; 2Pediatrics, Columbus University, New York, NY; 3Pediatrics, Washington University, St. Louis, MO
10:30 AM (218) Rejection in Presensitized Pediatric Heart Transplant Recipients With a Positive Donor Crossmatch Utilizing Perioperative Plasmapheresis and Cytolytic Therapy; D.B. Holt,1 D.M. Lublin,1 D.L.
Phelan,1 C.B. Huddleston,2 J.E. Saffitz,1 C.E. Canter,1 1Pediatrics, Washington University, St. Louis, MO; 2Pathology, Washington University, St. Louis, MO; 3Surgery, Washington University, St. Louis, MO 10:45 AM (219) Chronic High Epstein-Barr Virus Load Carrier State and Risk for Late Onset PTLD / Malignant Lymphoma; M.A. Binger,1 S.A. Miller,1 G.J. Boyle,1 M.G. Michaels,1 M. Green,1 R.M. Wadowsky,1 D.T. Rowe,1 V.O. Morell,1 E.S. Quivers,1 S.A. Webber,1 1Pediatrics, Children’s Hospital of Pittsburgh, Pittsburgh, PA 11:00 AM (220) Chronic Renal Failure in a 10-Year National Cohort of Pediatric Heart Transplant Recipients; C.K. Lee 11:10 AM (221) Coronary Stenosis Detection by 16-Slice Computed Tomography in Heart Transplant Patients: Comparison With Conventional Coronary Angiography and Impact on Clinical Management; G. Romeo, L. Houyel, J.-F. Paul, P. Brenot, J.-Y. Riou, C.-Y. Angel, Radiology, Marie-Lannelongue Hospital, Le Plessis-Robinson, France 11:50 AM (222) Mechanism and Prevention of Tricuspid Valve Regurgitation After Orthotopic Heart Transplantation; C. Krosalla,1 M. Dandel,1 S. Buz,1 F. Knollmann,1 Y.-G. Weng,1 M. Pasic,1 O. Grauhan,1 H.B. Lehmkuhl,1 R. Hetzer,1 1Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany; 1Department of Radiology, Charite-University Medicine Berlin, Berlin, Germany 11:55 AM (223) Effects of a Phosphodiesterase Type 5 Inhibitor (Sildenafil) Evaluated by 24-Hour Blood Pressure Monitoring and Exercise Capacity in Heart Transplanted Patients. A Double-Blind, Placebo-Controlled, Cross-Over, Randomized Study. Preliminary Results; G.V. Guimaraes, 12:05 PM (225) Improving Clinical Practice: Should We Give Influenza Vaccinations to Heart Transplant Patients? C. White-Williams,1 R. Brown,1 J. Kirklin,1 K. St. Clair,3 S. Keck,3 J. O’Donnell,1 D. Pitts,3 A. Van Bakel,1 1University of Alabama at Birmingham, Birmingham, AL; 2Massachusetts General Hospital, Boston, MA; 3Mid America Heart Institute of St. Luke’s Hospital, Knasas City, MO; 4Carian Health Partners, Indianapolis, IN; 5Medical University of South Carolina, Charleston, SC 12:10 PM (226) Comparison of Non-Invasive Versus Invasive Monitoring for Detection of Heart Transplant Rejection and Cardiac Vasculopathy in Cardiac-Transplant Recipients; E. Usta,1 C. Burgstahler,1 S. Schroeder,1 A. Kuettner,1 A.P. Kopp,1 G. Ziemer,1 H. Aebert,1 1Department of Thoracic, Cardiac and Vascular Surgery, University of Tuebingen; 2Department of Internal Medicine, Division of Cardiology; 3Department of Diagnostic Radiology, University of Tuebingen; 4Department of Cardiothoracic, Cardiac and Vascular Surgery, University of Tuebingen, Germany


12:30 PM (231) Aggressive Anti-Cytomegalovirus Prophylaxis and Acute Rejection in High Risk Patients: Beat the Virus and Prevent the Rejection; L. Potena, N. Banner.


12:45 AM-12:45 PM

MINI-ORAL POSTER PRESENTATION SESSION 6 (Salon CD)

Moderators: James B. Young, MD and Tom Egan, MD

11:45 AM (233) Anemia Is Common in Patients Referred for Heart Transplant and Hemoglobin Is Related to Prognostic Factors but Is Not an Independent Survival Predictor; A.B. Taegtmeyer, A.M. Crook, N.R. Banner, Transplant Unit, Harefield Hospital, Harefield, Middlesex, United Kingdom; Westminster Primary Care Trust, London, United Kingdom.

11:50 AM (234) Cardiac Power Output Is a Primary Determinant of B-Type Natriuretic Peptide Expression in Severe Heart Failure; M.R. Mehra, P.A. Uber, R.L. Scott, M.H. Park, M. Richie, H.O. Ventura, Cardiomyopathy and Heart Transplantation, Ochsner Clinic Foundation, New Orleans, LA.

11:55 AM (235) Simplified Prognostic Models for the Assessment of Ambulatory Heart Failure; I. Bolad, A. Taegtmeyer, S. Bond, S. Bentzen, N. Banner, Transplant Unit, Harefield Hospital, Middlesex, United Kingdom; Medical Statistics, Mount Vernon Hospital, Middlesex, United Kingdom.

NOO (236) Association of G3-Subclass Auto-Abs and NYHA Functional Status in Clinical Peripartum Cardiomyopathy; R. Warraich, J. Fett, M. Frenneaux, K. Sliwa, M. Yacoub, Cardiothoracic Surgery, Harefield Hospital, London, United Kingdom; Cardiology, Baragwanath Hospital, Johannesburg, South Africa; Adult Medicine, Hospital Albert Schweiter, Deschapelles, Haiti; Cardiology, Quebec Hospital, Birmingham, United Kingdom.

12:05 PM (237) Digoxin Therapy Increases Mortality Only in Female Heart Patients With a Prolonged QTc Interval; B. Vrtovec, R.M. Delgado, I.D. Gregoric, R. Radovancevic, B. Radovancevic, Transplant Research, Texas Heart Institute, Houston, TX.

12:10 PM (238) Glycine Supplementation to LPD Flush Preservation or as i.v.-Donor Preconditioning Improves Early Graft Function in a Porcine Single Left Lung Transplantation Model after 24 Hours of Cold Ischemia; B. Gohrbandt, S.P. Sommer, G. Wärnecke, S. Fischer, A. Haverich, M. Stuber, Thoracic and Cardiovascular Surgery, Hannover Medical School, Germany.

12:15 PM (239) The Role of the (Beta)-Adrenergic Receptor Kinase in Myocardial Dysfunction Following Brain Death; P.K. Pandalai, J.M. Lyons, J.Y. Duffy, K.M. McLean, C.J. Wagner, J.M. Pearl, W.H. Merrill, S.A. Akgiray, Division of Cardiac Surgery, University of Cincinnati College of Medicine, Cincinnati, OH.

12:20 PM (240) Recovery of Alveolar Micricirculation After Lung Transplantation in a Pig Model: Direct Visualization by OPS Imaging; N. Pizanis, V. Milekhin, M. Kamler, K. Kaiser, I. Aleksic, T. Ley, H. Jakob, Dept of Thoracic and Cardiovascular Surgery, West German Heart Center Essen, University Hospital of Essen, Essen, Germany.

12:25 PM (241) The Effect of Time From Donor Brain Death to Retrieval on Reperfusion Injury After Lung Transplantation; V.S. Avlonitis, J.A. Kirby, J.H. Dark, School of Surgical and Reproductive Sciences, University of Newcastle, Newcastle upon Tyne, United Kingdom.

12:30 PM (242) Should Transplant Centres Retrieve Their Own Hearts or Can Others Do It?; J.S. Ogbonnaya, C.A. Rogers, N.R. Banner, R.S. Bonser, On Behalf of the Steering Group, UK Cardiothoracic Transplant Audit, Clinical Effectiveness Unit, The Royal College of Surgeons of England, London, United Kingdom.
CONCURRENT SESSION 29
New Horizons and Unexpected Dangers in Cardiac Transplantation (Salons G-L)

Moderators: Jayan Parameshwar, FRCP and G. William Dec, MD


1:30 PM (245) Heart Transplantation for Adults With Congenital Heart Disease: A UK National Study; J.S. Ganesh, C.A. Rogers, R.S. Bonser, N.R. Banner, On Behalf of the Steering Group, UK Cardiotoracic Transplant Audit, Clinical Effectiveness Unit, The Royal College of Surgeons of England, London, United Kingdom

1:45 PM (246) Orthotopic Heart Transplantation in Patients With Cardiac Amyloidosis; S.S. Sudhakar, D.R. Bimalangshu, R.H. Falk, T.R. Spitzer, S.L. McAfee, W.G. Dec, D.G. Thomas, R.J. Hajjar, T.G. Wang, T.E. MacGillivray, J.C. Madsen, M.J. Semigran, Massachusetts General Hospital, Boston, MA


2:15 PM (248) Thromboembolism in Heart Transplantation: Role of Prothrombin G20210A and Factor V Leiden; S.G. Miriuka, S. Al-Faifi, C. Atkinson, S. Stewart, R.C. Trembath, N.W. Morrell, Department of Pathology, Papworth Hospital NHS Trust, Cambridge, United Kingdom

2:30 PM (249) Heart Transplantation in Patients With Marfan’s Syndrome; C. Knosalla, Y.-G. Weng, R. Hammerschmidt, O. Grauhan, H.B. Lehmkuhl, M. Dandel, R. Hetzer, Department of Cardiotoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany

1:15 PM-2:45 PM

CONCURRENT SESSION 30
Outcomes Before and After Lung Transplantation (Salon ABF)

Moderators: Lianne G. Singer, MD, FRCP and Reda Girgis, MB, BCh

1:15 PM (250) The Effect of Gender on Outcome in Human Lung Transplantation: The ISHLT Registry Experience; M. Sato, C. Gutierrez, H. Kaneda, M. Liu, T.K. Waddell, S. Keshavjee, Thoracic Surgery, Toronto General Hospital, Toronto, Ontario, Canada; Respiratory Medicine, Toronto General Hospital, Toronto, Ontario, Canada

1:30 PM (251) NT-proANP and BNP Predict the Risk of Death in Patients With Pulmonary Arterial Hypertension (PAH); S.M. Kawut, K.K. Berekashvili, E.H. Horn, A.C. Weldon, E.B. Rosenzweig, R.J. Barst, Department of Medicine, College of Physicians and Surgeons; Department of Pediatrics, College of Physicians and Surgeons, Columbia University, New York, NY

1:45 PM (252) The Effect of Recipient’s Age on Lung Transplant Outcome; C.A. Gutierrez, S. Al-Faifi, C. Chaparro, T. Waddell, D. Hadjiliadis, L. Singer, S. Keshavjee, M. Hutcheon, Toronto Lung Transplant Program, University Health Network, University of Toronto, Toronto, Ontario, Canada

2:00 PM (253) Evidence for Reduced SMAD Signalling in Diverse Forms of Pulmonary Arterial Hypertension (PAH); M.R. Southwood, C. Atkinson, S. Stewart, R.C. Trembath, N.W. Morrell, Department of Pathology, Papworth Hospital NHS Trust, Cambridge, United Kingdom

2:15 PM (254) Gender and Body Mass Index (BMI) Are Associated With Poor Functional Status One Year Post Lung Transplant Independent of Effects on Early Mortality; Sager, J.S. Kotloff, Ahyia, Simcox, Blumenthal, Mendez, Blikker, Pochettino, Christie, Division of Pulmonary, Allergy and Critical Care Medicine, University of Pennsylvania Medical Center; Division of Respiratory Services, University of Pennsylvania Medical Center.; Division of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine; Division of Thoracic Surgery, University of Pennsylvania Medical Center, Philadelphia, PA

2:30 PM (255) Survival Benefit in Patients With End Stage COPD After Lung Transplantation; G. Winkler, F. Jakusch, S. Geleff, M. Alber, W. Klepetko, Cardiothoracic Surgery, General Hospital Vienna, University Vienna, Vienna, Austria; Clinical Pathology, General Hospital Vienna, University Vienna, Austria

1:15 PM-2:45 PM
CONCURRENT SESSION 31
Aristotle’s Corner (Salon E)
Moderators: Anne Keogh, MBBS, MD and Bruce R. Rosengard, MD, FRCS, FACS

1:15 PM (256) The Future of Tolerance; J.C. Madsen, MD, Cardiac Surgery, Massachusetts General Hospital, Boston, MA
1:30 PM (257) The X-Files of Immunosuppression (or What’s Stronger in Transplant Medicine, Rationality or Irrationality?); A. Zuckermann, MD, Department of Cardio-Thoracic Surgery, Med-University of Vienna, Vienna, Austria
1:45 PM (258) Determination of the Differences in Cellular Three Dimensional Solvent Accessible Molecular Surfaces Generated by HLA Polymorphisms; Potential Role in Clinical Solid Organ Transplantation; O.E. Pajaro, MD, Thoracic Transplantation, Mayo Clinic, Jacksonville, FL
2:00 PM (259) Long-Term Outcome: What Do You Mean? J. Vanhaecke, MD, W. Droogné, MD, J. Van Cleemput, MD, W. Daenen, MD, Department of Cardiology, University Hospital Gasthuisberg, Leuven, Belgium; Department of Cardiac Surgery, University Hospital Gasthuisberg, Leuven, Belgium
2:15 PM (260) Society’s Self-Imposed Standards Infringe on Personal Liberty and Markedly Reduce Availability of Donor Organs; a Case for Self-Directed Heart Donation; D.S. Feldman, MD, D. Biniakiewicz, MD, C.V. Leier, MD, Department of Medicine/Division of Cardiology, The Ohio State University, Columbus, OH
2:30 PM (261) WITHDRAWN

1:15 PM-2:45 PM
CONCURRENT SESSION 32
Toward Tolerance and Experimental Cardiac Transplantation (Salon CD)
Moderators: Thomas D. Wekerle, MD and James F. George, PhD

1:15 PM (262) Selective CD28 Blockade by a Single–chain Fv Inhibits T Cell Proliferation and Prevents Acute Rejection in a Murine Model of Cardiac Allografttransplantation; T. Zhang, MD, H. Zhou, MD, G. Wu, MD, R.M. O’Hara Jr., MD, R.N. Pierson III, MD, A.M. Azimzadeh, MD, Division of Cardiac Surgery, University of Maryland, SOM and VAMC, Baltimore, MD; Wyeth Research, Cambridge, MA
1:30 PM (263) Overexpression of Neonatal Isoform of Cardiac Myosin in Donor Hearts Results in Prolongation of Graft Survival; M. Zwierzchoniewska, MD, J. Robbins, MD, R.C. Robbins, MD, E.V. Fedoseyeva, MD, CT Surgery, Stanford University, Stanford, CA; Molecular Cardiovascular Biology, Children’s Hospital, Cincinnati, OH
1:45 PM (264) Tolerance to Cardiac Allografts in Miniature Swine Using Donor-Specific Transfusions Combined With Cyclosporine but Not With Rapamycin; R. Hoerbelt, MD, T. Shoji, MD, A. Muniappan, MD, D.A. Guenther, MD, S.L. Houser, MD, J.S. Allan, MD, M. Bravard, MD, D.H. Sachs, MD, J.C. Madsen, MD, Surgery, Massachusetts General Hospital, TBRC, Charlestown, MA
2:00 PM (265) Heart and en-bloc Thymus Transplantation in Cynomolgus Monkeys; A. Muniappan, MD, D.R. Johnston, MD, D.A. Guenther, MD, T. Shoji, MD, S. Boskovic, MD, R. Hoerbelt, MD, S.L. Houser, MD, J.S. Allan, MD, K. Yamada, T. Kawai, MD, J.C. Wain, MD, D.H. Sachs, MD, J.C. Madsen, MD, Transplantation Biology Research Center, Massachusetts General Hospital, Boston, MA
2:15 PM (266) Cytotoxic Hyporesponsiveness Is Associated with High IL-10 mRNA Expression in Immunosuppressed Cardiac Allograft Patients; E. Dijke, MD, J. Velthuis, MD, A. Balk, MD, S. Korevaar, MD, L. Maat, MD, W. Weimar, MD, C. Baan, MD, Internal Medicine, Erasmus MC; Thorax Center, Erasmus MC, Rotterdam, Netherlands
2:30 PM (267) Interleukin-10 Reduces Endothelium-Dependent T Cell Costimulation Through Upregulation of Suppressor of Cytokine Signaling-3 and Immunoglobulin-Like Transcript 3 and 4; C.A. Gleissner, MD, R. Klingenberg, MD, M.H. Konstandin, MD, S. Celik, MD, T.J. Dengler, MD, Department of Cardiology, University of Heidelberg, Heidelberg, Germany

2:45 PM-3:00 PM
Coffee Break (Ballroom Pre-Function)

3:00 PM-4:30 PM
CLOSING PLENARY SESSION (Salons G-L)
Moderators: Mark L. Barr, MD and John Dark, MB, FRCS

3:00 PM Invited Lecture: Revisiting Listing Criteria for Heart, Mandeep Mehra, MD, Oschner Medical Institutions, New Orleans, LA; Mariell Jessup, MD, University of Pennsylvania, Philadelphia, PA; Eduardo Gronda, MD, Instituto Clinico Humanitas, Milan, Italy
3:20 PM Invited Lecture: Revisiting Listing Criteria for Lung, Jonathan B. Orens, MD, Johns Hopkins Hospital, Baltimore, MD
3:40 PM Invited Lecture: Primary Graft Dysfunction Update, Jason D. Christie, MD, University of
Pennsylvania, Philadelphia, PA
4:00 PM DEBATE: **Cell Therapy is a Myth**
**PRO:** Bruce R. Rosengard, MD, FRCS, FACS, Papworth Hospital Surgical Unit, Cambridge, United Kingdom
**CON:** Axel Haverich, MD, Hannover Medical School, Hannover, Germany

4:30 PM ADJOURN
EXHIBIT FLOOR PLANS
<table>
<thead>
<tr>
<th>EXHIBITING COMPANIES</th>
<th>Booth #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arrow International</td>
<td>108</td>
</tr>
<tr>
<td>Abbott laboratories</td>
<td>109</td>
</tr>
<tr>
<td>MedImmune, Inc.</td>
<td>112</td>
</tr>
<tr>
<td>Actelion</td>
<td>113</td>
</tr>
<tr>
<td>Home Solutions</td>
<td>114</td>
</tr>
<tr>
<td>Vitrolife, Inc.</td>
<td>115</td>
</tr>
<tr>
<td>ISHLT Registry</td>
<td>116</td>
</tr>
<tr>
<td>Ventracor Limited</td>
<td>117</td>
</tr>
<tr>
<td>United Network for Organ Sharing</td>
<td>118</td>
</tr>
<tr>
<td>MicroMed Technology, Inc.</td>
<td>208</td>
</tr>
<tr>
<td>Scios</td>
<td>212</td>
</tr>
<tr>
<td>Berlin Heart AG</td>
<td>216</td>
</tr>
<tr>
<td>Roche</td>
<td>300</td>
</tr>
<tr>
<td>XDx</td>
<td>312</td>
</tr>
<tr>
<td>Novartis</td>
<td>400</td>
</tr>
<tr>
<td>Thoratec Corporation</td>
<td>409</td>
</tr>
<tr>
<td>Chiron BioPharmaceuticals</td>
<td>412</td>
</tr>
<tr>
<td>Genzyme</td>
<td>413</td>
</tr>
<tr>
<td>Abiomed, Inc.</td>
<td>415</td>
</tr>
<tr>
<td>Fujisawa Healthcare, Inc.</td>
<td>500</td>
</tr>
<tr>
<td>World Heart Inc.</td>
<td>501</td>
</tr>
<tr>
<td>Therakos</td>
<td>505</td>
</tr>
<tr>
<td>Syncardia Systems, Inc.</td>
<td>507</td>
</tr>
<tr>
<td>Scanlan International, Inc.</td>
<td>508</td>
</tr>
<tr>
<td>Ceres Medical Systems, LLC</td>
<td>509</td>
</tr>
<tr>
<td>CHF Solutions, Inc.</td>
<td>510</td>
</tr>
<tr>
<td>Miller Pharmacal Group, Inc.</td>
<td>511</td>
</tr>
<tr>
<td>Vital Engineering</td>
<td>512</td>
</tr>
<tr>
<td>Medical Insight Research</td>
<td>513</td>
</tr>
<tr>
<td>Argon Medical Devices, Inc.</td>
<td>514</td>
</tr>
<tr>
<td>Elsevier</td>
<td>515</td>
</tr>
<tr>
<td>Haemoscope Corp</td>
<td>516</td>
</tr>
<tr>
<td>HRA Research</td>
<td>517</td>
</tr>
</tbody>
</table>
EXHIBITORS

**Abbott Laboratories**
200 Abbott Park Road
Abbott Park, IL 60064
Website: [www.abbott.com](http://www.abbott.com)

Abbott Laboratories is a global organization committed to researching Acute Decompensated Heart Failure (ADHF).

**Abiomed, Inc.**
22 Cherry Hill Drive
Danvers, MA 01923
Website: [www.abiomed.com](http://www.abiomed.com)

Based in Danvers, Massachusetts, ABIOMED, Inc. (pronounced “AB’-EE-O-MED”) is a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart. ABIOMED, which currently sells the BVS® 5000 Biventricular Support System and the AB5000™ Circulatory Support System, is the market leader in devices for the temporary support of patients with failing but potentially recoverable hearts. In September 2004, ABIOMED applied for initial FDA market approval for the AbioCor Implantable Replacement Heart to treat a defined subset of irreversible end-stage heart failure patients under a Humanitarian Device Exemption.

**Actelion Pharmaceuticals**

**Argon Medical Devices, Inc.**
1445 Flat Creek Road
Athens, TX 75751
Website: [www.argonmedical.com](http://www.argonmedical.com)


**Arrow International**
The LionHeart™ LVAD is now CE marked and is the only fully implantable LVAD designed for destination therapy of heart failure patients. The LionHeart features pulsatile flow with transcutaneous energy transmission offering patient’s hope and a good quality of life.

Astellas Pharma, Inc.
(Formerly Fujisawa Healthcare, Inc.)
3 Parkway North
Deerfield, IL 60015
Website: www.astellas.com

Berlin Heart AG
Wiesenweg 10
Berlin, Germany 12242
Website: www.berlinheart.com

INCOR® - implantable third generation axial flow LVAD system with unique contact free magnetically levitated impeller.
EXCOR® - extracorporeal pneumatically driven Uni/BiVAD system with a full range of pumps and cannulas for support of all patient sizes from newborn to adult.

Ceres Medical Systems, LLC
4665 Sweetwater Blvd
Suite 104
Sugar Land, TX 77479

CHF Solutions, Inc.
7601 Northland Dr.
Ste 170
Brooklyn Park, MN 55428
Website: www.chfsolutions.com

Aquapheresis enables predictable, mechanical isotonic solute removal with no clinically significant impact on electrolytes in volume overloaded patients. An advanced form of therapeutic apheresis with selective ultrafiltration, aquapheresis using the Aquadex system (CHF Solutions, Inc.) and its low extracorporeal blood volume (37 cc) and blood flow (20-40 cc/min) empowers a physician to select safe, predictable isotonic saline removal rates (10-500 ml/hour) using a variety of venous access sites (central, peripheral, midline, standard IV). Able to be performed in virtually any clinical setting, the safety, efficacy, and efficiency of the
Aquadex make aquapheresis the gold standard in salt and water removal.

Chiron BioPharmaceuticals
4560 Horton Street
Emeryville, CA  94608
Website:  www.chiron.com

Chiron Corporation, headquartered in Emeryville, California, is a global pharmaceutical company that leverages a diverse business model to develop and commercialize high-value products that make a difference in people's lives. The company has a strategic focus on cancer and infectious disease to develop products from its platforms in proteins, small molecules and vaccines. The company commercializes its products through three business units: BioPharmaceuticals, Vaccines and Blood Testing. For more information about Chiron, visit the company's website at www.chiron.com.

Elsevier
625 Walnut St
Suite 300
Philadelphia, PA  19106
Website:  www.elsevier.com


Please visit us to browse our complete selection of publications in Transplantation, Surgery, and Cardiovascular Medicine including books, periodicals and software.

Genzyme
500 Kendall Street
Cambridge, MA  02478
Website:  www.genzyme.com

Genzyme is a leader in the effort to address a range of unmet medical needs. The company’s products and services are focused on rare inherited disorders, kidney disease, orthopaedics, transplant and immune disease, cancer, and diagnostic testing. Genzyme’s commitment to innovation continues today with a substantial research and development program focused on genetic diseases, immune system disorders, heart disease, and cancer.

Haemoscope Corp.
TEG® Hemostasis Analyzer: Point-of-care whole-blood instrument that provides a complete picture of all phases of patient hemostasis; delivers an analysis more comprehensive and complete in conventional, isolated laboratory tests; helps clinicians make faster, more well-informed diagnoses for better treatment and clinical outcomes; reduces costs associated with decreased blood product and pharmaceutical use.

**Home Solutions, Infusion Therapy**

**HRA Research**
400 Lanidex Plaza
Parsippany, NJ 07054
Website: [www.hraresearch.com](http://www.hraresearch.com)

Our team of experienced interviewers will be distributing carefully developed questionnaires. We’ll be gathering the answers to vital marketing and clinical questions—answers that can affect the introduction of new products or the continuation of existing health care products and services.

**ISHLT Registry**
700 North 4th Street
Richmond, VA 23219

The International Registry for Heart and Lung Transplantation provides on-going, current information on the worldwide thoracic organ transplantation experience. Additionally, we maintain the Mechanical Circulatory Support Device Database to collect data on the implantation and outcomes of patients receiving cardiac assist devices. The data, utilized for scientific study, contributes to the body of knowledge regarding thoracic transplantation and cardiac device management. Our goal is to identify overall best practices for improving cardiothoracic patient care.

This year the exhibit will make your center-specific information available for your review. In addition, members can view data screens from both the ISHLT Registry and the MCSD Database and receive guidance on enrollment, training on submission of data and instructions for submitting special data requests.

**Medical Insight Research**
25 Burlington Mall Road, 6th Floor
Medical Insight Research is an economic consulting firm focused on the pharmaceutical and biotechnology industry. They provide a variety of services including pricing research, product positioning, and launch planning.

**MedImmune, Inc.**
One MedImmune Way
Gaithersburg, MO 20878
Web site: [www.medimmune.com](http://www.medimmune.com)

MedImmune, Inc. is dedicated to advancing science and medicine to help people live better lives. The biotechnology company is focused on pediatric infectious diseases, cancer and inflammatory diseases. CytoGam® (cytomegalovirus immune globulin intravenous (human) (CMV-IVIG) is indicated for prophylaxis associated with transplantation of the kidney, lung, liver, pancreas and heart.

**MicroMed Technology, Inc.**
8965 Interchange Drive
Houston, TX 77054
Web site: [www.micromedtech.com](http://www.micromedtech.com)

MicroMed, a leader in miniaturized implantable VADs, will present the DeBakey VAD® and the DeBakey VAD Child. Developed in collaboration with NASA, Drs. Michael DeBakey and George Noon, the DeBakey VAD is currently in pivotal trials across the US for evaluation as both BTT and Destination Therapy. The DeBakey VAD is 1/10 the size of pulsatile devices designed to be highly durable and provide full left ventricular support in a broad range of BSA. The DeBakey VAD Child is the only commercially approved (HDE) implantable VAD for children. They both have been awarded the CE mark for distribution in Europe.

**Miller Pharmacal Group, Inc.**
350 Randy Road, Ste. #2
Carol Stream, Il 60188
Web site: [www.millerpharmaca.com](http://www.millerpharmaca.com)

Miller Pharmacal features the oral magnesium supplement “MG Plus Protein.” Currently in use at many transplant centers (solid organ and BMT), “MG Plus Protein” treats and prevents the hypomagnesia caused by immunosuppressants, without causing the GI disturbances common with magnesium oxide.

The diarrhea commonly caused by magnesium oxide complicates maintaining immunosuppressant levels; in addition to being a large quality-of-life for patients (and a
major cause of noncompliance).

“MG Plus Protein” is inexpensive, a 500-tablet bottle is available for $31.00; a fraction of the cost of “Slow-Mag.” Professional samples and an indigent patient program are available.

**Novartis Pharmaceuticals Corporation**  
One Health Plaza  
East Hanover, NJ 07936  
Web Site: www.Novartis/transplantation

**Roche**  
PBC Congresses  
Bldg 74/40.409  
4040 Basel, Switzerland  
Web site: www.roche.com

**Scios, Inc.**  
6500 Paseo Padre Parkway  
Fremont, CA 94555  
Web site: www.hoovers.com

Scios Inc., a Johnson & Johnson biopharmaceutical company, is dedicated to changing the way Heart failure is treated and is developing new and exciting therapeutics for cardiovascular disease, inflammatory disease and cancer. With its flagship product, Natrecor® (nesiritide), Scios proved that its winning combination of integrated research, clinical experience, and passionate commitment to patients with unmet medical needs can make a difference in the management of disease. Applying the same experience and commitment, Scios is advancing a new potential treatment for advanced chronic heart failure and is developing novel potential therapies in inflammatory disease and cancer for patients with unmet medical needs.

**Scanlan International, Inc.**  
One Scanlan Plaza  
Saint Paul, MN 55107  
Website: www.scanlangroup.com

Highest quality surgical products designed and manufactured by the Scanlan family since 1921. Offering a wide array of Titanium Needle Holders, forceps and clamps and stainless steel instrumentation, including Resano forceps, Scanlan SUPER CUT™ and ULTRA SHARP® scissors, Scanlan DIAMOND DUST™ instrumentation. Scanlan offers a wide variety of custom modifications to accommodate surgeons’ specific needs. Single-use products include SCANLAN® Surg-I-Loop® PLUS, single-use aorta/vein punch, A/C LOCATOR® and RADIOMARK® graft markers, Vascu-Stat® single-use
bulldog clamps, as well as SURG-I-PAW® jaw covers and SOFT-GRIP™ fabric clamp covers.

Scios, Inc.  
6500 Paseo Padre Parkway  
Freemont, CA  94555  
Web Site:  www.scios.com

Syncardia Systems, Inc.  
1992 E. Silverlake Road  
Tucson, AZ  85713  
Website:  www.syncardia.com

Thoratec Corporation  
6035 Stoneridge Dr.  
Pleasanton, CA  94588

Thoratec Corporation, the pioneer of and leader in ventricular assist devices (VADs) offers a full line of technologically advanced devices for the restoration of hemodynamics designed to meet the needs and provide a better quality of life for the widest range of patients experiencing heart failure. Only Thoratec offers both FDA approved implantable and paracorporeal ventricular assist devices for a full range of indications including postcardiotomy support, bridge to cardiac transplantation and Destination Therapy. Our HeartMate LVAS, Thoratec VAD and IVAD™ Systems are ideally suited for short to long term, left, right or biventricular support in patients of almost any size.

Therakos  
437 Creamery Way  
Exton, PA  19341  
Web site:  www.therakos.com

United Network for Organ Sharing (UNOS)  
700 N. 4th Street  
Richmond, VA  23219  
Web site:  www.unos.com

UNOS is a 501 (c) 3 non-profit, scientific, educational and charitable organization that oversees the national Organ Procurement and Transplantation Network (OPTN). Responsibilities include: facilitating organ donation through research, education and advocacy; managing the U.S. transplant waiting list matching donors to recipients; maintaining a database that monitors U.S. transplant recipients; and, through private, charitable funding working to increase organ availability and continuously improve the outcomes and quality of life of transplant candidates and recipients.
The VentrAssist™ LVAS Left Ventricular Assist System
The VentrAssist™ Left Ventricular Assist System (LVAS) has been developed as a solution for patients requiring circulatory support, be that as destination therapy or bridge to transplant. It is capable of delivering 10L/min at 120mmHg. The unique, hydrodynamically suspended “open flow rotor” eliminates points of wear, local heating and flow disturbance which can lead to device failure and thrombus formation. In pre-clinical and clinical trialing the VentrAssist™ LVAS has shown exceedingly low levels of hemolysis. Its small size suits it for use in a wide range of patients.

Vital Engineering provides training and educational programs for physicians and other health care providers as well as on-site training and technical support prior to, during and following device implantation. Vital Engineering has the knowledge and resources to improve patient care from surgery through discharge planning and outpatient care. Our clinical experience equips the artificial organ industry with the ultimate product quality improvement from emerging to experienced companies. Vital Engineering offers many partnerships benefits to patients, clinicians, hospitals, and industry.

Perfadex is a colloid containing lightly buffered extracellular low K+ electrolyte solution for rapid cooling, perfusion and storage of organs in connection with transplantation. Perfadex is the gold standard in lung preservation.

World Heart Inc.
7799 Pardee Lane
Oakland, CA 94621
Web site: www.worldheart.com
WorldHeart, a worldwide pioneer and technology leader in mechanical circulatory support systems, is a global medical device company with offices in Oakland, California, Heesch, The Netherlands, and Ottawa, Canada. WorldHeart is currently focused on the development and commercialization of ventricular assist devices. Its Novarcor® LVAS, which has unprecedented reliability and durability, is well established in the marketplace. It is the first ventricular assist device to provide a recipient with more than 6 years of circulatory support and continues to hold the industry record for longest support on a single device, over 45 years.

WorldHeart recently acquired Medquest, developer of a magnetically levitated centrifugal rotary blood pump making WorldHeart the only company with small, silent, next-generation pulsatile and rotary systems under development, as well as having the most durable and reliable current-generation pulsatile device in the market today.

XDx
701 Gateway Blvd, Suite 100
South San Francisco, CA 94080
Web site: www.xdx.com
FUTURE ISHLT MEETINGS

November 11-12 , 2005
7th ISHLT Fall Education Meeting
Immediately Prior to the AHA Annual Meeting
Dallas, TX, USA

APRIL 5-8, 2006
ISHLT 26th ANNUAL MEETING AND SCIENTIFIC SESSIONS
Madrid, Spain

APRIL 25-28, 2007
ISHLT 27th ANNUAL MEETING AND SCIENTIFIC SESSIONS
San Francisco, CA